Schizotypal personality disorder

Last updated
Schizotypal personality disorder
Other namesSchizotypal disorder
Specialty Psychiatry, clinical psychology
Symptoms Ideas of reference, unusual beliefs, perceptual Illusions, odd thinking and speech, suspiciousness, inappropriate affect, strange behavior, lack of friends, paranoid social anxiety, dissociation (e.g. derealization, depersonalization, amnesia, fugue, etc.) [1] [2] [3]
Complications Schizophrenia, substance use disorder, major depressive disorder
Usual onset10–20 years old
Durationchronic
Causes Genetics; childhood neglect; childhood abuse
Risk factors Family history
Diagnostic method Based on symptoms
Differential diagnosis Cluster A personality disorders, borderline personality disorder, avoidant personality disorder, autism spectrum disorder, social anxiety disorder, ADHD-PI (ADD), dissociative identity disorder [1] [2] [3]
Treatment Cognitive-behavioral therapy, Metacognitive therapy, Cognitive remediation therapy
Medication Antipsychotics, Antidepressants
Prognosis Typically poor, although significant improvements can be made
FrequencyEstimated 3% of general population

Schizotypal personality disorder (StPD or SPD), also known as schizotypal disorder, is a cluster A personality disorder. [4] [5] The Diagnostic and Statistical Manual of Mental Disorders (DSM) classification describes the disorder specifically as a personality disorder characterized by thought disorder, paranoia, a characteristic form of social anxiety, derealization, transient psychosis, and unconventional beliefs. People with this disorder feel pronounced discomfort in forming and maintaining social connections with other people, primarily due to the belief that other people harbor negative thoughts and views about them. [6] Peculiar speech mannerisms and socially unexpected modes of dress are also characteristic. Schizotypal people may react oddly in conversations, not respond, or talk to themselves. [6] They frequently interpret situations as being strange or having unusual meanings for them; paranormal and superstitious beliefs are common. Schizotypal people usually disagree with the suggestion that their thoughts and behaviors are a 'disorder' and seek medical attention for depression or anxiety instead. Schizotypal personality disorder occurs in approximately 3% of the general population and is more commonly diagnosed in males. [7]

Contents

History

StPD was introduced in 1980 in the DSM-III. [8] Its inclusion provided a new classification for schizophrenia-spectrum disorders and of personality disorders that were previously unspecified. [9] [8] Its diagnosis was developed through differentiating the classifications of borderline personality disorder, of which some of the diagnosed population demonstrated schizophrenia-spectrum traits. [9] [8] When the separation of borderline personality disorder and StPD was originally suggested by Spitzer and Endicott, Siever and Gunderson opposed the distinction. [10] [9] Siever and Gunderson's opposition to Spitzer and Endicott was that StPD was related to schizophrenia. [11] Spitzer and Endicott stated "We believe, as do the authors, that the evidence for the genetic relationship between Schizotypal features and Chronic Schizophrenia is suggestive rather than proven". [9] StPD was included in the DSM-IV and the DSM-V and saw little change in its diagnosis. [8]

Epidemiology

The reported prevalence of StPD in community studies ranges from 1.37% in a Norwegian sample, to 4.6% in an American sample. [12] A large American study found a lifetime prevalence of 3.9%, with somewhat higher rates among men (4.2%) than women (3.7%). [7] It may be uncommon in clinical populations, with reported rates of up to 1.9%. [12] It has been estimated to be prevalent among up to 5.2% of the general population. [13] Together with other cluster A personality disorders, it is also very common among homeless people who show up at drop-in centers, according to a 2008 New York study. The study did not address homeless people who do not show up at drop-in centers. [14] Schizotypal disorder may be overdiagnosed in Russia and other post-Soviet states. [15]

Prognosis

People with StPD usually had symptoms of schizotypal personality disorder in childhood. [16] Traits of StPD usually remain consistently present over time, [17] [18] although can fluctuate greatly in severity and stability. [19] [20] DSM characterizes StPD as having nine major symptoms: ideas of reference, odd/magical beliefs, social anxiety, not having close friends, odd or eccentric behavior, odd speech, unusual perceptions, suspiciousness, schizo-obsessive behaviors [21] and constricted affect. [22] There may be gender differences in the symptomology of men and women with StPD. [23] Women with the disorder might be more likely to have less severe cognitive deficits, and more severe social anxiety and magical thinking. [24] [25] [26] People with StPD are more likely to only have a high school education, to be unemployed, [27] and to have significant functional impairment. [28] The two traits of StPD which are least likely to change are paranoia and abnormal experiences. [20]

Compared to those without StPD, adolescents with StPD spend more time socialising on the Internet, such as on forums, chat rooms and cooperative computer games, and spend less time socialising in "real life". [29]

Obsessive-compulsive disorder coexistence

People who are treatment resistant to obsessive–compulsive disorder behavioral therapy and medication that also display odd or eccentric behaviors could contribute to the coexistence of obsessive-compulsive disorder with schizotypal disorder. [21]

Etiology

Genetic

People who have relatives with schizotypy, [30] [31] [32] mood disorders, [33] or other disorders on the schizophrenia spectrum are at a higher likelihood of developing StPD. [34] [32] [35] Although environmental factors likely play an important role in the onset of the disorder. The COMT Val158Met polymorphism and its Val or Met allele are suspected to be associated with Schizotypal personality disorder. [36] [37] [38] [39] This is because these genes affect dopamine production in the brain. [40] [41] [42] This is a neurochemical thought to be associated with schizotypal traits. [43] [44] The gene may also contribute to decreased levels of gray matter in the prefrontal cortex. [45] [46] This may lead to impaired capacities for decision-making, [47] speech, [48] cognitive flexibility, [49] and altered perceptual experiences. [50] The rs1006737 polymorphism of the CACNA1C gene is also believed to have a part in schizotypal symptoms. [51] It may lead to a significantly increased physiological response to stress through the cortisol awakening response in the brain. [52] [53] [54] [55] It may also negatively affect reward processing in the brain and lead to anhedonia or depression in patients. [56] [57] These factors possibly lead to the development of Schizotypal traits. [58] The zinc-finger protein ZNF804A likely affects the levels of paranoia, anxiety, and ideas of reference in StPD. [59] [60] [61] This gene is also thought to negatively impact attention in people with StPD. [62] It may lead to an increased level of white matter volume in the frontal lobe. [63] Another gene, the NOTCH4 is thought to relate to Schizophrenia spectrum disorders. [64] [65] It can lead to disruptions in the occipital cortex, and therefore symptoms of schizotypy. [66] The GLRA1 and the p250GAP genes are also potentially associated with StPD. [67] [68] [69] It may lead to abnormally low levels of Glutamic acids in the NDMA receptors, which impairs memory and learning. [70] [71] [72] [73] StPD may stem from abnormalities in Chromosome 22. [74] [75] [76]

Neurological

Exposure to influenza during week 23 of gestation is associated with a higher likelihood of developing StPD. Poor nutrition in childhood may also contribute to the onset of StPD by altering the course of brain development. [77] Numerous areas of the brain are thought to be associated with StPD. Higher levels of dopamine in the brain, [78] [79] possibly specifically the D1 receptor, [80] [81] [82] might contribute to the development of StPD. StPD is associated with heightened dopaminergic activity in the striatum. [83] [84] [85] [86] Their symptoms may also stem from higher presynaptic dopamine release. [87] [88] [89] [90] People with StPD may also have decreased volumes of grey or white matter in their caudate nucleus, [91] [92] which leads to difficulties in speech. [93] [94] [95] [96] People with StPD likely have a reduced volume in their temporal lobes, [97] [98] [99] possibly specifically the left hemisphere. The reduced levels of gray matter in these areas may be linked to their negative symptoms. [100] Reduced volume of gray or white matter in the superior temporal gyrus or the transverse temporal gyrus are thought to lead to issues with speech, [23] [101] [102] [103] memory, and hallucinations. [104] [105] Deficits in the gray matter volume of the temporal lobe and prefrontal cortex are likely associated with impairments in cognitive function, sensory processing, speech, executive function, decision-making, and emotional processing present in people with StPD. [106] [107] StPD symptoms may also be influenced by reduced internal capsule, [108] [109] [110] which carries information to the cerebral cortex. [111] People with StPD can also have impairments in the uncinate fasciculus, which connects parts of the limbic system. [112] People with StPD have reduced levels of gray matter in their middle frontal gyrus and Brodmann area 10. [113] Although, not as reduced as patients with Schizophrenia. [113] Possibly preventing them from developing schizophrenia. [114] Increased gyrification in gyri by the cerebellum may lead to dysconnectivity in the brain, and therefore, schizotypal symptoms. [115] [116] They may also have a hyporeactive, [117] or hyperreactive amygdala. [118] As well as hyperactive pituitary glands and putamens. [119] [120] It is also possible that lower capacities for prepulse inhibition plays a role in StPD. [121] [122] [123] [124] Research has suggested that people with StPD can have higher concentrations of Homovanillic acids. [125] Abnormalities in the cave of septum pellucidum may also be present. [126] In people predisposed to the development of Schizophrenia spectrum disorders, the consumption of cannabis can induce the onset of StPD or other disorders with psychotic symptoms. [127] [128] [129] [130]

Environmental

Unique environmental factors, which differ from shared sibling experiences, have been found to play a role in the development of StPD and its dimensions. There is evidence to suggest that parenting styles, early separation, childhood trauma, and childhood neglect can lead to the development of schizotypal traits. [131] [132] [133] Neglect, abuse, stress, [134] trauma, [135] [136] [137] or family dysfunction during childhood may increase the risk of developing schizotypal personality disorder. [138] [139] [140] There is also evidence indicating that disruptions in brain development during the prenatal period could affect the development of StPD. [141] Over time, children learn to interpret social cues and respond appropriately but for unknown reasons this process does not work well for people with this disorder. [142] During childhood, people with StPD may have seen little emotional expression from their parents. Another possibility is that they were excessively criticized or felt like they were constantly under threat, [143] potentially resulting in the onset of social anxiety, strange thinking patterns, [144] and blunted affect present in StPD. [145] [144] [146] Their difficulties in social situations might eventually cause the individual to withdraw from most social interactions, thus leading to asociality. [147] Children with schizotypal symptoms usually are more likely to indulge in internal fantasies, [148] more anxious, socially isolated, and more sensitive to criticism. [149] People with the most severe cases of StPD usually have a combination of childhood trauma and a genetic basis for their condition. [150] [151]

Signs and symptoms

People with StPD can feel intense paranoia. Paranoia (158822147).jpeg
People with StPD can feel intense paranoia.
People with StPD can have abnormal sensory experiences. Rotating snakes illusion.svg
People with StPD can have abnormal sensory experiences.

Magical ideation

Odd and magical thinking is common among people with StPD. [152] [153] [154] They are more likely to believe in supernatural phenomena and entities. [155] [156] [157] [158] It is common for people with StPD to experience severe social anxiety and have paranoid ideation. [159] [160] Ideas of reference are common in people with StPD. [161] [162] [163] They can feel as if expressing themselves is dangerous. They may also feel that others are more competent, and have deeply entrenched and pervasive insecurities. Strange thinking patterns may be a defense mechanism against these feelings. [164] People with StPD usually have limited levels of self-awareness. [165] They may believe others think of them more negatively than they actually do. [166]

Affect

Patients with StPD can have difficulties in recognizing their or others' emotions. [167] [168] This can extend to difficulties expressing emotion. [169] [170] They may have limited responses to others' emotions and can be ambivalent. [171] It is common for people with StPD to derive limited joy from activities. [172] [173] [174] People with StPD are typically more socially isolated and uninterested in social situations than most people, [175] [176] [177] although they can be socially active on the internet. [178] Depersonalization, [179] [180] derealization, [181] boredom, [182] and internal fantasies are common in patients with StPD. Abnormal facial expressions are also common in people with StPD, and they can have aberrant eye movements and difficulty responding to stimuli. [183] [184] [185] [186] [187] They are more prone to substance abuse or suicidal ideation. [188] [189] Another epidemiological study on suicidal behavior in StPD found that, even when accounting for sociodemographic factors, people with StPD were 1.51 times more likely to attempt suicide. [138]

Cognitive impairments

People with StPD tend to have cognitive impairments. [190] They can have abnormal perceptional and sensory experiences such as illusions. [191] [192] For example, someone with StPD may perceive colors as lighter or darker than others perceive them. [193] Facial perception may also be difficult for people with the disorder. [194] [195] [196] [197] They can see others as deformed, may misrecognize them, or can feel as if they are alien to them. [193] People with StPD can have difficulty processing information such as speech or language. [198] [199] [200] They are more likely to speak slowly, with less fluctuation in pitch, [201] and long pauses between speech. Patients with StPD may have a lower odor detection threshold, [202] and can have impaired auditory or olfactory processing. [203] It is also common for people with StPD to struggle with context processing, [204] [205] which cause them to form loose connections between events. [206] In addition, people with StPD can have decreased capacities for multisensory integration or contrast sensitivity, [207] [208] [209] [210] either hyperreactive or impaired reactions to sensory input, [211] [212] [213] slower response times, [187] impaired attention, [214] [215] [147] poorer postural control, [216] and difficulties with decision-making. [217] [218] They can have difficulties in memory, [219] [220] [221] and may have frequent intrusive memories of events. [222] It is common for people with StPD to feel déjà vu or as if they can accurately predict future events due to abnormalities in the brain's memory storage. [223]

Treatment

Medication

Ball-and-stick model of Risperidone, a drug used to treat StPD Risperidone-3D-balls.png
Ball-and-stick model of Risperidone, a drug used to treat StPD
Model of Cognitive behavioral therapy, a type of therapy used to treat StPD Cognitive behavioral therapy - basic tenets.svg
Model of Cognitive behavioral therapy, a type of therapy used to treat StPD

StPD is rarely seen as the primary reason for treatment in a clinical setting, but it often occurs as a comorbid finding with other mental disorders. When patients with StPD have prescribed pharmaceuticals, they are usually prescribed antipsychotics, [224] [225] [226] however, the use of neuroleptic drugs in the schizotypal population is in great doubt. [227] The antipsychotics which show promise as treatments for StPD include olanzapine, [228] risperidone, [229] [230] haloperidol, [231] and thiothixene. [232] The antidepressant fluoxetine may also be helpful. [233] [234] While people with schizotypal personality disorder and other attenuated psychotic-spectrum disorders may have a good outcome with neuroleptics in the short term, long-term follow-up suggests significant impairment in daily functioning compared to schizotypal and even schizophrenic people without antipsychotic drug exposure. [235] Positive, negative, and depressive symptoms were shown to be improved by the used of olanzapine, an antipsychotic. [233] Those with comorbid OCD and StPD were most positively affected by the use of olanzapine, and showed worse outcomes with the use of clomipramine, an antidepressant. [230] Antidepressants are also sometimes prescribed, whether for StPD proper or for comorbid anxiety and depression. [227] [230] However, there is some ambiguity in the efficacy of antidepressants, as many studies have only tested people with StPD and comorbid obsessive-compulsive disorder or borderline personality disorder. They have shown little efficacy for treating dysthymia and anhedonia related to StPD. [5] Both of these medications are the most frequently prescribed medication for StPD, though the use and efficacy of them should be evaluated differently for every case. [233] The use of stimulants has also shown some efficacy, especially for those with worsened cognitive and attentional issues. Patients that suffer from concurrent psychosis should be monitored more closely if stimulants are used as part of their treatment. [5] Other drugs which may be effective include pergolide, [236] guanfacine, [237] [238] [239] [240] and dihydrexidine. [241] [242] [243]

Therapy

According to Theodore Millon, schizotypal personality disorder is one of the easiest personality disorders to identify but one of the most difficult to treat with psychotherapy. [244] Cognitive remediation therapy, [238] [245] [246] metacognitive therapy, supportive psychotherapy, [247] social skills training [248] and cognitive-behavioral therapy can be effective treatments for the disorder. [249] [250] Increased social interaction with others may be able to help limit symptoms of StPD. [251] Support is especially important for schizotypal patients with predominant paranoid symptoms, because they may have difficulties even in highly structured groups. [252] Persons with StPD usually consider themselves to be simply eccentric or nonconformist; the degree to which they consider their social nonconformity a problem differs from the degree to which it is considered a problem in psychiatry. It is difficult to gain rapport with people with StPD because increasing familiarity and intimacy often increase their level of anxiety and discomfort. [253] Therapy for StPD must be flexible to face emergencies or unique challenges. [247]

Diagnosis

Formal diagnostic criteria

StPD is characterized by 5 or more of the following: [254]

These symptoms must have begun by early adulthood.

Differential diagnosis

DiagnosisDetails
Other mental disorders with psychotic symptoms Unlike delusional disorder, schizophrenia, or mood disorders with psychotic features, StPD is not characterized by a persistent period of psychotic symptoms. StPD symptoms must also persist when psychotic symptoms are not present. [16] [17]
Personality change due to another medical conditionSymptoms similar to those of StPD can appear due to other medical conditions that affect the central nervous system or substance use disorders.
Other personality disordersOther personality disorders can have symptoms similar to StPD. People with schizotypal personality disorder, paranoid personality disorder and schizoid personality disorder can also be socially detached and have blunted affects, but without the cognitive or perceptual distortions of StPD. Individuals with StPD and people with avoidant personality disorder can have limited close relationships. However, people with AvPD rarely have the eccentric behaviour of StPD. Psychotic-like symptoms can also appear in borderline personality disorder, but those with BPD fear social isolation while those with StPD are comfortable with it. People with StPD are also usually less impulsive than people with BPD. Individuals with narcissistic personality disorder may also appear socially alienated, however, this is due to fears of having flaws noticed by others. [12]

Differential diagnosis with the following disorders should also be considered:

Screening

There are various methods of screening for schizotypal personality. The Schizotypal Personality Questionnaire (SPQ) measures nine traits of StPD using a self-report assessment. [255] The nine traits referenced are Ideas of Reference, Excessive Social Anxiety, Odd Beliefs or Magical Thinking, Unusual Perceptual Experiences, Odd or Eccentric Behavior, No Close Friends, Odd Speech, Constricted Affect, and Suspiciousness. A study found that of the participants who scored in the top 10th percentile of all the SPQ scores, 55% were clinically diagnosed with StPD. [256] It has been adapted into a computerized adaptive version, known as the SPQ-CAT. [257] A method that measures the risk of developing psychosis through self-reports is the Wisconsin Schizotypy Scale (WSS). [258] The WSS divides schizotypal personality traits into 4 scales for Perceptual Aberration, Magical Ideation, Revised Social Anhedonia, and Physical Anhedonia. [259] [260] A comparison of the SPQ and the WSS suggests that these measures should be cautiously used for screening of StPD. [260]

When screening for StPD, it is difficult to distinguish between schizotypal personality disorder and autism spectrum disorder. [261] In order to develop better screening tools, researchers are looking into the importance of ipseity disturbance, which is characteristic of schizophrenia spectrum disorders such as StPD but not of autism. [262] [261]

Millon's subtypes

Theodore Millon proposes two subtypes of schizotypal personality. [244] [263] Any individual with schizotypal personality disorder may exhibit either one of the following somewhat different subtypes (note that Millon believes it is rare for a personality to show one pure variant, but rather a mixture of one major variant with one or more secondary variants):

SubtypeDescriptionPersonality traits
Insipid schizotypalA structural exaggeration of the passive-detached pattern. It includes schizoid, depressive and dependent features.Sense of strangeness and nonbeing; overtly drab, sluggish, inexpressive; internally bland, barren, indifferent, and insensitive; obscured, vague, and tangential thoughts.
Timorous schizotypalA structural exaggeration of the active-detached pattern. It includes avoidant and negativistic features.Warily apprehensive, watchful, suspicious, guarded, shrinking, deadens excess sensitivity; alienated from self and others; intentionally blocks, reverses, or disqualifies own thoughts.

Millon's typology of personality disorders was influential in the development of the DSM-III, particularly with respect to distinguishing between schizoid, schizotypal and avoidant personality disorders. [264] These had previously been considered different surface-level expressions of the same underlying personality structure, and some psychologists, particularly those working in psychoanalytic or psychodynamic traditions, still take these personality disorders to be essentially similar. [265] [266]

Common comorbidities

See also

Related Research Articles

<span class="mw-page-title-main">Schizophrenia</span> Mental disorder with psychotic symptoms

Schizophrenia is a mental disorder characterized by reoccurring episodes of psychosis that are correlated with a general misperception of reality. Other common signs include hallucinations, delusions, disorganized thinking, social withdrawal, and flat affect. Symptoms develop gradually and typically begin during young adulthood and are never resolved. There is no objective diagnostic test; diagnosis is based on observed behavior, a psychiatric history that includes the person's reported experiences, and reports of others familiar with the person. For a diagnosis of schizophrenia, the described symptoms need to have been present for at least six months or one month. Many people with schizophrenia have other mental disorders, especially substance use disorders, depressive disorders, anxiety disorders, and obsessive–compulsive disorder.

<span class="mw-page-title-main">Clozapine</span> Atypical antipsychotic medication

Clozapine is a psychiatric medication and is the first atypical antipsychotic to be discovered. It is primarily used to treat people with schizophrenia and schizoaffective disorder who have had an inadequate response to two other antipsychotics or who have been unable to tolerate other drugs due to extrapyramidal side effects. It is also used for the treatment of psychosis in Parkinson's disease.

<span class="mw-page-title-main">Schizoid personality disorder</span> Medical condition

Schizoid personality disorder is a personality disorder characterized by a lack of interest in social relationships, a tendency toward a solitary or sheltered lifestyle, secretiveness, emotional coldness, detachment, and apathy. Affected individuals may be unable to form intimate attachments to others and simultaneously possess a rich and elaborate but exclusively internal fantasy world. Other associated features include stilted speech, a lack of deriving enjoyment from most activities, feeling as though one is an "observer" rather than a participant in life, an inability to tolerate emotional expectations of others, apparent indifference when praised or criticized, a degree of asexuality, and idiosyncratic moral or political beliefs.

<span class="mw-page-title-main">Anhedonia</span> Inability to feel pleasure

Anhedonia is a diverse array of deficits in hedonic function, including reduced motivation or ability to experience pleasure. While earlier definitions emphasized the inability to experience pleasure, anhedonia is currently used by researchers to refer to reduced motivation, reduced anticipatory pleasure (wanting), reduced consummatory pleasure (liking), and deficits in reinforcement learning. In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), anhedonia is a component of depressive disorders, substance-related disorders, psychotic disorders, and personality disorders, where it is defined by either a reduced ability to experience pleasure, or a diminished interest in engaging in previously pleasurable activities. While the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) does not explicitly mention anhedonia, the depressive symptom analogous to anhedonia as described in the DSM-5 is a loss of interest or pleasure.

<span class="mw-page-title-main">Avoidant personality disorder</span> Personality disorder

Avoidant personality disorder (AvPD) or Anxious personality disorder is a Cluster C personality disorder characterized by excessive social anxiety and inhibition, fear of intimacy, severe feelings of inadequacy and inferiority, and an overreliance on avoidance of feared stimuli as a maladaptive coping method. Those affected typically display a pattern of extreme sensitivity to negative evaluation and rejection, a belief that one is socially inept or personally unappealing to others, and avoidance of social interaction despite a strong desire for it. It appears to affect an approximately equal number of men and women.

In psychology, schizotypy is a theoretical concept that posits a continuum of personality characteristics and experiences, ranging from normal dissociative, imaginative states to extreme states of mind related to psychosis, especially schizophrenia. The continuum of personality proposed in schizotypy is in contrast to a categorical view of psychosis, wherein psychosis is considered a particular state of mind, which the person either has or does not have.

A spectrum disorder is a disorder that includes a range of linked conditions, sometimes also extending to include singular symptoms and traits. The different elements of a spectrum either have a similar appearance or are thought to be caused by the same underlying mechanism. In either case, a spectrum approach is taken because there appears to be "not a unitary disorder but rather a syndrome composed of subgroups". The spectrum may represent a range of severity, comprising relatively "severe" mental disorders through to relatively "mild and nonclinical deficits".

Schizophrenia is a neurodevelopmental disorder with no precise or single cause. Schizophrenia is thought to arise from multiple mechanisms and complex gene–environment interactions with vulnerability factors. Risk factors of schizophrenia have been identified and include genetic factors, environmental factors such as experiences in life and exposures in a person's environment, and also the function of a person's brain at it develops. The interactions of these risk factors are intricate, as numerous and diverse medical insults from conception to adulthood can be involved. Many theories have been proposed including the combination of genetic and environmental factors may lead to deficits in the neural circuits that affect sensory input and cognitive functions.

In genetic epidemiology, endophenotype is a term used to separate behavioral symptoms into more stable phenotypes with a clear genetic connection. By seeing the EP notion as a special case of a larger collection of multivariate genetic models, which may be fitted using currently accessible methodology, it is possible to maximize its valuable potential lessons for etiological study in psychiatric disorders. The concept was coined by Bernard John and Kenneth R. Lewis in a 1966 paper attempting to explain the geographic distribution of grasshoppers. They claimed that the particular geographic distribution could not be explained by the obvious and external "exophenotype" of the grasshoppers, but instead must be explained by their microscopic and internal "endophenotype". The endophenotype idea represents the influence of two important conceptual currents in biology and psychology research. An adequate technology would be required to perceive the endophenotype, which represents an unobservable latent entity that cannot be directly observed with the unaided naked eye. In the investigation of anxiety and affective disorders, the endophenotype idea has gained popularity.

<span class="mw-page-title-main">Patrick McGorry</span> Australian psychiatrist

Patrick Dennistoun McGorry is an Irish-born Australian psychiatrist known for his development of the early intervention services for emerging mental disorders in young people.

Substance-induced psychosis is a form of psychosis that is attributed to substance intoxication. It is a psychosis that results from the effects of chemicals or drugs. Various psychoactive substances have been implicated in causing or worsening psychosis in users.

The causes of schizophrenia that underlie the development of schizophrenia, a psychiatric disorder, are complex and not clearly understood. A number of hypotheses including the dopamine hypothesis, and the glutamate hypothesis have been put forward in an attempt to explain the link between altered brain function and the symptoms and development of schizophrenia.

<span class="mw-page-title-main">Prognosis of schizophrenia</span>

The prognosis of schizophrenia is varied at the individual level. In general it has great human and economics costs. It results in a decreased life expectancy of 12–15 years primarily due to its association with obesity, little exercise, and smoking, while an increased rate of suicide plays a lesser role. These differences in life expectancy increased between the 1970s and 1990s, and between the 1990s and 2000s. This difference has not substantially changed in Finland for example – where there is a health system with open access to care.

The diagnosis of schizophrenia, a psychotic disorder, is based on criteria in either the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, or the World Health Organization's International Classification of Diseases (ICD). Clinical assessment of schizophrenia is carried out by a mental health professional based on observed behavior, reported experiences, and reports of others familiar with the person. Diagnosis is usually made by a psychiatrist. Associated symptoms occur along a continuum in the population and must reach a certain severity and level of impairment before a diagnosis is made. Schizophrenia has a prevalence rate of 0.3-0.7% in the United States.

The relationship between schizoid personality disorder (SzPD) and avoidant personality disorder (AvPD) has been a subject of controversy for decades.

At risk mental state is the clinical presentation of those considered at risk of developing psychosis or schizophrenia. Such states were formerly considered treated as prodromes, emerging symptoms of psychosis, but this view is no longer prevalent as a prodromal period can not be confirmed unless the emergence of the condition has occurred.

<span class="mw-page-title-main">Imprinted brain hypothesis</span> Conjecture on the causes of autism and psychosis

The imprinted brain hypothesis is an unsubstantiated hypothesis in evolutionary psychology regarding the causes of autism spectrum and schizophrenia spectrum disorders, first presented by Bernard Crespi and Christopher Badcock in 2008. It claims that certain autistic and schizotypal traits are opposites, and that this implies the etiology of the two conditions must be at odds.

The evolution of schizophrenia refers to the theory of natural selection working in favor of selecting traits that are characteristic of the disorder. Positive symptoms are features that are not present in healthy individuals but appear as a result of the disease process. These include visual and/or auditory hallucinations, delusions, paranoia, and major thought disorders. Negative symptoms refer to features that are normally present but are reduced or absent as a result of the disease process, including social withdrawal, apathy, anhedonia, alogia, and behavioral perseveration. Cognitive symptoms of schizophrenia involve disturbances in executive functions, working memory impairment, and inability to sustain attention.

A self-disorder, also called ipseity disturbance, is a psychological phenomenon of disruption or diminishing of a person's minimal self – the fundamental sense that one's experiences are truly one's own. People with self-disorder feel that their internal experiences are actually external; for example, they may experience their own thoughts as coming from outside themselves, whether in the form of true auditory hallucinations or merely as a vague sense that their thoughts do not belong to them.

The University of California, San Diego Performance-Based Skills Assessment (UPSA) was created by Dr. Thomas L. Patterson to provide a more reliable measure of every day functioning in patients with schizophrenia than the previously utilized methods such as self-report, clinician ratings or direct observation.

References

  1. 1 2 Ghorbali A, Shaeiri M, Fesharaki M (July 2021). "Relationship between Dissociative Experiences and Schizotypal Personality Traits: Mediating Role of Inferential Confusion". Iranian Journal of Psychiatry. 17 (1): 52–60. doi:10.18502/ijps.v17i1.8049. PMC   8994835 . PMID   35480133.
  2. 1 2 Kaplan AM, Smith CM (20 July 2021). "Schizotypal personality disorder disguised as dissociative identity disorder". BMJ Case Reports. 14 (7): e243454. doi:10.1136/bcr-2021-243454. PMC   8292736 . PMID   34285029.
  3. 1 2 Giesbrecht T, Merckelbach H, Kater M, Sluis AF (October 2007). "Why dissociation and schizotypy overlap: the joint influence of fantasy proneness, cognitive failures, and childhood trauma". The Journal of Nervous and Mental Disease. 195 (10): 812–818. doi:10.1097/NMD.0b013e3181568137. ISSN   0022-3018. PMID   18043521. S2CID   45086235 . Retrieved 5 March 2023.
  4. ↑ Sartorius N, Henderson A, Strotzka H, Lipowski Z, Yu-cun S, You-xin X, et al. "The ICD-10 Classification of Mental and Behavioural Disorders Clinical descriptions and diagnostic guidelines" (PDF). www.who.int. World Health Organization. bluebook.doc. pp. 77, 83–4. Retrieved 23 June 2021.
  5. 1 2 3 4 Rosell DR, Futterman SE, McMaster A, Siever LJ (July 2014). "Schizotypal personality disorder: a current review". Current Psychiatry Reports. 16 (7): 452. doi:10.1007/s11920-014-0452-1. PMC   4182925 . PMID   24828284.
  6. 1 2 Schacter DL, Gilbert DT, Wegner DM (2010). Psychology. Worth Publishers.
  7. 1 2 Pulay AJ, Stinson FS, Dawson DA, Goldstein RB, Chou SP, Huang B, et al. (2009). "Prevalence, correlates, disability, and comorbidity of DSM-IV schizotypal personality disorder: results from the wave 2 national epidemiologic survey on alcohol and related conditions". Primary Care Companion to the Journal of Clinical Psychiatry. 11 (2): 53–67. doi:10.4088/PCC.08m00679. PMC   2707116 . PMID   19617934.
  8. 1 2 3 4 Rosell, Futterman, McMaster, Siever (July 16, 2014). "Schizotypal Personality Disorder: A Current Review". Current Psychiatry Reports. 16 (7): 452. doi:10.1007/s11920-014-0452-1. PMC   4182925 . PMID   24828284.
  9. 1 2 3 4 Spitzer, Endicott (1979). "Justification for Separating Schizotypal and Borderline Personality Disorders". Schizophrenia Bulletin. 5 (1): 95–104. doi: 10.1093/schbul/5.1.95 . PMID   441693 . Retrieved 2023-04-10.
  10. ↑ "APA PsycNet". psycnet.apa.org. Retrieved 2023-04-10.
  11. ↑ Siever LJ, Bernstein DP, Silverman JM (31 Jan 2011). "Schizotypal Personality Disorder: A Review of Its Current Status". Journal of Personality Disorders. 5 (2): 178–193. doi:10.1521/pedi.1991.5.2.178. ISSN   0885-579X.
  12. 1 2 3 Diagnostic and statistical manual of mental disorders : DSM-5. American Psychiatric Association, American Psychiatric Association. 2013. pp.  655–659. ISBN   978-0-89042-555-8. OCLC   830807378.
  13. 1 2 3 4 Pulay AJ, Stinson FS, Dawson DA, Goldstein RB, Chou SP, Huang B, et al. (2009-04-16). "Prevalence, correlates, disability, and comorbidity of DSM-IV schizotypal personality disorder: results from the wave 2 national epidemiologic survey on alcohol and related conditions". Primary Care Companion to the Journal of Clinical Psychiatry. 11 (2): 53–67. doi:10.4088/PCC.08m00679. PMC   2707116 . PMID   19617934.
  14. ↑ Connolly AJ, Cobb-Richardson P, Ball SA (December 2008). "Personality disorders in homeless drop-in center clients" (PDF). Journal of Personality Disorders. 22 (6): 573–588. doi:10.1521/pedi.2008.22.6.573. PMID   19072678. Archived from the original (PDF) on 2009-06-17.
  15. ↑ Быкова А. Ю., Беккер Р. А., Быков Ю. В. О трудностях дифференциальной диагностики между первичным деперсонализационно-дереализационным расстройством и шизотипическим расстройством // Siberian Journal of Life Sciences & Agriculture. — 2022. — Т. 14. — №. 1.
  16. 1 2 Jones HP, Testa RR, Ross N, Seal ML, Pantelis C, Tonge B (2015-01-06). "The Melbourne assessment of Schizotypy in kids: a useful measure of childhood schizotypal personality disorder". BioMed Research International. 2015: 635732. doi: 10.1155/2015/635732 . PMC   4300034 . PMID   25629050.
  17. 1 2 Shea MT, Stout R, Gunderson J, Morey LC, Grilo CM, McGlashan T, et al. (December 2002). "Short-term diagnostic stability of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders". The American Journal of Psychiatry. 159 (12): 2036–2041. doi:10.1176/appi.ajp.159.12.2036. PMID   12450953.
  18. ↑ Alphen SP, Heijnen-Kohl SM (2019-01-25). "Personality Disorders in Later Life". Oxford Research Encyclopedia of Psychology. doi:10.1093/acrefore/9780190236557.013.420. ISBN   978-0-19-023655-7.
  19. ↑ Grilo CM, Sanislow CA, Gunderson JG, Pagano ME, Yen S, Zanarini MC, et al. (October 2004). "Two-year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders". Journal of Consulting and Clinical Psychology. 72 (5): 767–775. doi:10.1037/0022-006X.72.5.767. PMC   3289406 . PMID   15482035.
  20. 1 2 McGlashan TH, Grilo CM, Sanislow CA, Ralevski E, Morey LC, Gunderson JG, et al. (May 2005). "Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders: toward a hybrid model of axis II disorders". The American Journal of Psychiatry. 162 (5): 883–889. doi:10.1176/appi.ajp.162.5.883. PMC   3272783 . PMID   15863789.
  21. 1 2 Baer L (1986-03-01). "Coexistent Obsessive-Compulsive Disorder and Schizotypal Personality Disorder: A Poor Prognostic Indicator". Archives of General Psychiatry. 43 (3): 296. doi:10.1001/archpsyc.1986.01800030114016. ISSN   0003-990X. PMID   3954553.
  22. ↑ Xi C, Cai Y, Peng S, Lian J, Tu D (2019-12-05). "A diagnostic classification version of Schizotypal Personality Questionnaire using diagnostic classification models". International Journal of Methods in Psychiatric Research. 29 (1): e1807. doi:10.1002/mpr.1807. ISSN   1049-8931. PMC   7051843 . PMID   31808226.
  23. 1 2 Dickey CC, McCarley RW, Voglmaier MM, Niznikiewicz MA, Seidman LJ, Demeo S, et al. (December 2003). "An MRI study of superior temporal gyrus volume in women with schizotypal personality disorder". The American Journal of Psychiatry. 160 (12): 2198–2201. doi:10.1176/appi.ajp.160.12.2198. PMC   2826718 . PMID   14638590.
  24. ↑ Voglmaier MM, Seidman LJ, Niznikiewicz MA, Dickey CC, Shenton ME, McCarley RW (April 2005). "A comparative profile analysis of neuropsychological function in men and women with schizotypal personality disorder". Schizophrenia Research. 74 (1): 43–49. doi:10.1016/j.schres.2004.09.013. PMC   2772126 . PMID   15694753. S2CID   17916499.
  25. ↑ Voglmaier MM, Seidman LJ, Niznikiewicz MA, Madan A, Dickey CC, Shenton ME, et al. (December 2009). "Dichotic listening in schizotypal personality disorder: evidence for gender and laterality effects". Schizophrenia Research. 115 (2–3): 290–292. doi:10.1016/j.schres.2009.04.028. PMC   3879145 . PMID   19464150. S2CID   20730801.
  26. ↑ Bora E, Baysan Arabaci L (October 2009). "Effect of age and gender on schizotypal personality traits in the normal population". Psychiatry and Clinical Neurosciences. 63 (5): 663–669. doi: 10.1111/j.1440-1819.2009.02011.x . PMID   19674380. S2CID   22072954.
  27. ↑ McClure MM, Harvey PD, Bowie CR, Iacoviello B, Siever LJ (March 2013). "Functional outcomes, functional capacity, and cognitive impairment in schizotypal personality disorder". Schizophrenia Research. 144 (1–3): 146–150. doi:10.1016/j.schres.2012.12.012. PMC   3572293 . PMID   23375943.
  28. ↑ Skodol AE, Gunderson JG, McGlashan TH, Dyck IR, Stout RL, Bender DS, et al. (February 2002). "Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder". The American Journal of Psychiatry. 159 (2): 276–283. doi:10.1176/appi.ajp.159.2.276. PMID   11823271.
  29. ↑ Mittal VA, Tessner KD, Walker EF (2007). "Elevated social Internet use and schizotypal personality disorder in adolescents". Schizophrenia Research. 94 (1–3): 50–57. doi:10.1016/j.schres.2007.04.009. PMC   2323598 . PMID   17532188.
  30. ↑ Debbané M, Eliez S, Badoud D, Conus P, Flückiger R, Schultze-Lutter F (March 2015). "Developing psychosis and its risk states through the lens of schizotypy". Schizophrenia Bulletin. 41 (Suppl 2): S396–S407. doi:10.1093/schbul/sbu176. PMC   4373628 . PMID   25548386.
  31. ↑ Schultze-Lutter F, Nenadic I, Grant P (2019). "Psychosis and Schizophrenia-Spectrum Personality Disorders Require Early Detection on Different Symptom Dimensions". Frontiers in Psychiatry. 10: 476. doi: 10.3389/fpsyt.2019.00476 . PMC   6637034 . PMID   31354543.
  32. 1 2 Kemp KC, Bathery AJ, Barrantes-Vidal N, Kwapil TR (2020-08-10). "A brief questionnaire measure of multidimensional schizotypy predicts interview-rated symptoms and impairment". PLOS ONE. 15 (8): e0237614. Bibcode:2020PLoSO..1537614K. doi: 10.1371/journal.pone.0237614 . PMC   7416934 . PMID   32776979.
  33. ↑ Squires-Wheeler E, Skodol AE, Bassett A, Erlenmeyer-Kimling L (1989). "DSM-III-R schizotypal personality traits in offspring of schizophrenic disorder, affective disorder, and normal control parents". Journal of Psychiatric Research. 23 (3–4): 229–239. doi:10.1016/0022-3956(89)90028-9. PMC   3160972 . PMID   2635220.
  34. ↑ Tarbox SI, Pogue-Geile MF (November 2011). "A multivariate perspective on schizotypy and familial association with schizophrenia: a review". Clinical Psychology Review. 31 (7): 1169–1182. doi:10.1016/j.cpr.2011.07.002. PMC   3176972 . PMID   21855827.
  35. ↑ Torti MC, Buzzanca A, Squarcione C, Salerno C, Mirigliani A, Di Fabio F, et al. (October 2013). "Schizotypy and personality profiles of Cluster A in a group of schizophrenic patients and their siblings". BMC Psychiatry. 13 (1): 245. doi: 10.1186/1471-244X-13-245 . PMC   3856523 . PMID   24094118.
  36. ↑ Skilleter AJ, Weickert CS, Moustafa AA, Gendy R, Chan M, Arifin N, et al. (November 2014). "BDNF val66met genotype and schizotypal personality traits interact to influence probabilistic association learning". Behavioural Brain Research. 274: 137–142. doi: 10.1016/j.bbr.2014.07.041 . PMID   25125238. S2CID   18041054.
  37. ↑ Siever LJ (2005). "Endophenotypes in the personality disorders". Dialogues in Clinical Neuroscience. 7 (2): 139–151. doi:10.31887/DCNS.2005.7.2/lsiever. PMC   3181730 . PMID   16262209.
  38. ↑ Docherty AR, Sponheim SR (November 2008). "Anhedonia as a phenotype for the Val158Met COMT polymorphism in relatives of patients with schizophrenia". Journal of Abnormal Psychology. 117 (4): 788–798. doi:10.1037/a0013745. PMC   2936689 . PMID   19025226.
  39. ↑ Leung WW, McClure MM, Siever LJ, Barch DM, Harvey PD (December 2007). "Catechol-O-methyltransferase Val158Met genotype in healthy and personality disorder individuals: Preliminary results from an examination of cognitive tests hypothetically differentially sensitive to dopamine functions". Neuropsychiatric Disease and Treatment. 3 (6): 925–934. doi: 10.2147/NDT.S1500 . PMC   2656336 . PMID   19300629. S2CID   8816485.
  40. ↑ Sheldrick AJ, Krug A, Markov V, Leube D, Michel TM, Zerres K, et al. (September 2008). "Effect of COMT val158met genotype on cognition and personality". European Psychiatry. 23 (6): 385–389. doi:10.1016/j.eurpsy.2008.05.002. PMID   18755576. S2CID   45960144.
  41. ↑ Steiner GZ, Fernandez FM, Coles M, Karamacoska D, Barkus E, Broyd SJ, et al. (July 2019). "Interrogating the Relationship Between Schizotypy, the Catechol-O-Methyltransferase (COMT) Val158Met Polymorphism, and Neuronal Oscillatory Activity". Cerebral Cortex. 29 (7): 3048–3058. doi:10.1093/cercor/bhy171. PMID   30084963.
  42. ↑ Barnett JH, Jones PB, Robbins TW, Müller U (May 2007). "Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls". Molecular Psychiatry. 12 (5): 502–509. doi: 10.1038/sj.mp.4001973 . PMID   17325717. S2CID   764484.
  43. ↑ Silberschmidt AL, Sponheim SR (March 2008). "Personality in relation to genetic liability for schizophrenia and bipolar disorder: differential associations with the COMT Val 108/158 Met polymorphism". Schizophrenia Research. 100 (1–3): 316–324. doi:10.1016/j.schres.2007.12.467. PMC   2682527 . PMID   18201871.
  44. ↑ Giakoumaki SG, Roussos P, Bitsios P (December 2008). "Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism". Neuropsychopharmacology. 33 (13): 3058–3068. doi: 10.1038/npp.2008.82 . PMID   18536698. S2CID   3130616.
  45. ↑ Rodríguez-Toscano E, Martínez K, Fraguas D, Janssen J, Pina-Camacho L, Arias B, et al. (2022-04-01). "Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis". Revista de Psiquiatría y Salud Mental. 15 (2): 74–87. doi:10.1016/j.rpsm.2021.11.002. ISSN   1888-9891. PMID   35840287. S2CID   244126716.
  46. ↑ Thermenos HW, Keshavan MS, Juelich RJ, Molokotos E, Whitfield-Gabrieli S, Brent BK, et al. (October 2013). "A review of neuroimaging studies of young relatives of individuals with schizophrenia: a developmental perspective from schizotaxia to schizophrenia". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 162B (7): 604–635. doi: 10.1002/ajmg.b.32170 . PMID   24132894. S2CID   32797877.
  47. ↑ Roussos P, Giakoumaki SG, Rogdaki M, Pavlakis S, Frangou S, Bitsios P (November 2008). "Prepulse inhibition of the startle reflex depends on the catechol O-methyltransferase Val158Met gene polymorphism". Psychological Medicine. 38 (11): 1651–1658. doi:10.1017/S0033291708002912. PMID   18261249. S2CID   29311411.
  48. ↑ Krug A, Markov V, Sheldrick A, Krach S, Jansen A, Zerres K, et al. (December 2009). "The effect of the COMT val(158)met polymorphism on neural correlates of semantic verbal fluency". European Archives of Psychiatry and Clinical Neuroscience. 259 (8): 459–465. doi:10.1007/s00406-009-0010-8. PMID   19381707. S2CID   20321844.
  49. ↑ Nolan KA, Bilder RM, Lachman HM, Volavka J (February 2004). "Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility". The American Journal of Psychiatry. 161 (2): 359–361. doi:10.1176/appi.ajp.161.2.359. PMID   14754787.
  50. ↑ Demily C, Louchart-de-la-Chapelle S, Nkam I, Ramoz N, Denise P, Nicolas A, et al. (December 2016). "Does COMT val158met polymorphism influence P50 sensory gating, eye tracking or saccadic inhibition dysfunctions in schizophrenia?". Psychiatry Research. 246: 738–744. doi:10.1016/j.psychres.2016.07.066. PMID   27825784. S2CID   207452788.
  51. ↑ Krautheim JT, Straube B, Dannlowski U, Pyka M, Schneider-Hassloff H, Drexler R, et al. (March 2018). "Outgroup emotion processing in the vACC is modulated by childhood trauma and CACNA1C risk variant". Social Cognitive and Affective Neuroscience. 13 (3): 341–348. doi:10.1093/scan/nsy004. PMC   5836282 . PMID   29385621.
  52. ↑ Klaus K, Butler K, Gutierrez H, Durrant SJ, Pennington K (July 2018). "Interactive effects of early life stress and CACNA1C genotype on cortisol awakening response" (PDF). Biological Psychology. 136: 22–28. doi:10.1016/j.biopsycho.2018.05.002. PMID   29733866. S2CID   13679165.
  53. ↑ Youngs MA (2021). Investigating Individual Differences in Acute Psychosocial Stress Reactivity and Evaluation of Wearable Devices for Heart Rate Variability Measurement (mres thesis). University of Lincoln.
  54. ↑ Weinstein DD, Diforio D, Schiffman J, Walker E, Bonsall R (April 1999). "Minor physical anomalies, dermatoglyphic asymmetries, and cortisol levels in adolescents with schizotypal personality disorder". The American Journal of Psychiatry. 156 (4): 617–623. doi:10.1176/ajp.156.4.617. PMID   10200743. S2CID   9094296.
  55. ↑ Pasparakis E, Koiliari E, Zouraraki C, Tsapakis EM, Roussos P, Giakoumaki SG, et al. (June 2015). "The effects of the CACNA1C rs1006737 A/G on affective startle modulation in healthy males". European Psychiatry. 30 (4): 492–498. doi:10.1016/j.eurpsy.2015.03.004. PMID   25841664. S2CID   30938090.
  56. ↑ Lancaster TM, Heerey EA, Mantripragada K, Linden DE (October 2014). "CACNA1C risk variant affects reward responsiveness in healthy individuals". Translational Psychiatry. 4 (10): e461. doi:10.1038/tp.2014.100. PMC   4350510 . PMID   25290268. S2CID   1654916.
  57. ↑ Green EK, Grozeva D, Jones I, Jones L, Kirov G, Caesar S, et al. (October 2010). "The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia". Molecular Psychiatry. 15 (10): 1016–1022. doi:10.1038/mp.2009.49. PMC   3011210 . PMID   19621016. S2CID   6297556.
  58. ↑ Roussos P, Bitsios P, Giakoumaki SG, McClure MM, Hazlett EA, New AS, et al. (March 2013). "CACNA1C as a risk factor for schizotypal personality disorder and schizotypy in healthy individuals". Psychiatry Research. 206 (1): 122–123. doi:10.1016/j.psychres.2012.08.039. PMC   4176879 . PMID   22985546.
  59. ↑ Stefanis NC, Hatzimanolis A, Avramopoulos D, Smyrnis N, Evdokimidis I, Stefanis CN, et al. (November 2013). "Variation in psychosis gene ZNF804A is associated with a refined schizotypy phenotype but not neurocognitive performance in a large young male population". Schizophrenia Bulletin. 39 (6): 1252–1260. doi:10.1093/schbul/sbs110. PMC   3796069 . PMID   23155182.
  60. ↑ Lencz T, Szeszko PR, DeRosse P, Burdick KE, Bromet EJ, Bilder RM, et al. (October 2010). "A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes". Neuropsychopharmacology. 35 (11): 2284–2291. doi:10.1038/npp.2010.102. PMC   2939918 . PMID   20664580. S2CID   19216888.
  61. ↑ Yasuda Y, Hashimoto R, Ohi K, Fukumoto M, Umeda-Yano S, Yamamori H, et al. (May 2011). "Impact on schizotypal personality trait of a genome-wide supported psychosis variant of the ZNF804A gene". Neuroscience Letters. 495 (3): 216–220. doi:10.1016/j.neulet.2011.03.069. PMID   21457757. S2CID   45364708.
  62. ↑ Del Re EC, Bergen SE, Mesholam-Gately RI, Niznikiewicz MA, Goldstein JM, Woo TU, et al. (January 2014). "Analysis of schizophrenia-related genes and electrophysiological measures reveals ZNF804A association with amplitude of P300b elicited by novel sounds". Translational Psychiatry. 4 (1): e346. doi:10.1038/tp.2013.117. PMC   3905227 . PMID   24424392. S2CID   16062551.
  63. ↑ Wassink TH, Epping EA, Rudd D, Axelsen M, Ziebell S, Fleming FW, et al. (September 2012). "Influence of ZNF804a on brain structure volumes and symptom severity in individuals with schizophrenia". Archives of General Psychiatry. 69 (9): 885–892. doi:10.1001/archgenpsychiatry.2011.2116. PMC   3852666 . PMID   22945618.
  64. ↑ Wassink TH, Nopoulos P, Pietila J, Crowe RR, Andreasen NC (April 2003). "NOTCH4 and the frontal lobe in schizophrenia". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 118B (1): 1–7. doi: 10.1002/ajmg.b.10071 . PMID   12627456. S2CID   23380937.
  65. ↑ DiLalla LF, McCrary M, Diaz E (September 2017). "A review of endophenotypes in schizophrenia and autism: The next phase for understanding genetic etiologies". American Journal of Medical Genetics. Part C, Seminars in Medical Genetics. 175 (3): 354–361. doi:10.1002/ajmg.c.31566. PMID   28661580. S2CID   4441493.
  66. ↑ Xie X, Zu M, Zhang L, Bai T, Wei L, Huang W, et al. (July 2020). "A common variant of the NOTCH4 gene modulates functional connectivity of the occipital cortex and its relationship with schizotypal traits". BMC Psychiatry. 20 (1): 363. doi: 10.1186/s12888-020-02773-z . PMC   7346398 . PMID   32646407.
  67. ↑ Bulbena-Cabre A, Bassir Nia A, Perez-Rodriguez MM (August 2018). "Current Knowledge on Gene-Environment Interactions in Personality Disorders: an Update". Current Psychiatry Reports. 20 (9): 74. doi:10.1007/s11920-018-0934-7. PMID   30094700. S2CID   51954090.
  68. ↑ Köse SS, Erbaş O (2020). "Personality disorders diagnosis, causes, and treatments". Demiroglu Science University Florence Nightingale Journal of Transplantation. 5 (2): 022–031. doi: 10.5606/dsufnjt.2020.013 . ISSN   2667-6680. S2CID   234447745.
  69. ↑ Ma G, Fan H, Shen C, Wang W (June 2016). "Genetic and Neuroimaging Features of Personality Disorders: State of the Art". Neuroscience Bulletin. 32 (3): 286–306. doi:10.1007/s12264-016-0027-8. PMC   5563771 . PMID   27037690.
  70. ↑ Vora AK, Fisher AM, New AS, Hazlett EA, McNamara M, Yuan Q, et al. (June 2018). "Dimensional Traits of Schizotypy Associated With Glycine Receptor GLRA1 Polymorphism: An Exploratory Candidate-Gene Association Study". Journal of Personality Disorders. 32 (3): 421–432. doi:10.1521/pedi_2017_31_303. PMC   5856645 . PMID   28758885.
  71. ↑ Ohi K, Hashimoto R, Nakazawa T, Okada T, Yasuda Y, Yamamori H, et al. (2012-04-18). "The p250GAP gene is associated with risk for schizophrenia and schizotypal personality traits". PLOS ONE. 7 (4): e35696. Bibcode:2012PLoSO...735696O. doi: 10.1371/journal.pone.0035696 . PMC   3329470 . PMID   22530067.
  72. ↑ Walter EE, Fernandez F, Snelling M, Barkus E (2016). "Genetic Consideration of Schizotypal Traits: A Review". Frontiers in Psychology. 7: 1769. doi: 10.3389/fpsyg.2016.01769 . PMC   5108787 . PMID   27895608.
  73. ↑ Lett TA, Voineskos AN, Kennedy JL, Levine B, Daskalakis ZJ (March 2014). "Treating working memory deficits in schizophrenia: a review of the neurobiology". Biological Psychiatry. 75 (5): 361–370. doi: 10.1016/j.biopsych.2013.07.026 . PMID   24011822. S2CID   23781971.
  74. ↑ Esterberg ML, Trotman HD, Brasfield JL, Compton MT, Walker EF (September 2008). "Childhood and current autistic features in adolescents with schizotypal personality disorder". Schizophrenia Research. 104 (1–3): 265–273. doi:10.1016/j.schres.2008.04.029. PMC   4416647 . PMID   18554872.
  75. ↑ Shapiro DI, Cubells JF, Ousley OY, Rockers K, Walker EF (June 2011). "Prodromal symptoms in adolescents with 22q11.2 deletion syndrome and schizotypal personality disorder". Schizophrenia Research. 129 (1): 20–28. doi:10.1016/j.schres.2011.03.030. PMC   3100383 . PMID   21507614.
  76. ↑ Esposito CM, Enrico P, Sciortino D, Caletti E, Marchetti GB, Cesaretti C, et al. (2021). "Case Report: The Association Between Chromosomal Anomalies and Cluster A Personality Disorders: The Case of Two Siblings With 16p11.2 Deletion and a Review of the Literature". Frontiers in Psychiatry. 12: 689359. doi: 10.3389/fpsyt.2021.689359 . PMC   8217436 . PMID   34168584.
  77. ↑ Venables PH, Raine A (August 2012). "Poor nutrition at age 3 and schizotypal personality at age 23: the mediating role of age 11 cognitive functioning". The American Journal of Psychiatry. 169 (8): 822–830. doi:10.1176/appi.ajp.2012.11081173. PMID   22772085.
  78. ↑ Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, et al. (December 2011). "Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study". The American Journal of Psychiatry. 168 (12): 1311–1317. doi:10.1176/appi.ajp.2011.11010160. PMC   3682447 . PMID   21768612.
  79. ↑ Woodward ND, Cowan RL, Park S, Ansari MS, Baldwin RM, Li R, et al. (April 2011). "Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions". The American Journal of Psychiatry. 168 (4): 418–426. doi:10.1176/appi.ajp.2010.10020165. PMC   3770457 . PMID   21159728.
  80. ↑ Pekcec A, Schülert N, Stierstorfer B, Deiana S, Dorner-Ciossek C, Rosenbrock H (July 2018). "Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance". British Journal of Pharmacology. 175 (14): 3021–3033. doi:10.1111/bph.14350. PMC   6016630 . PMID   29726015.
  81. ↑ Chemerinski E, Siever LJ, Koenigsberg HW (2005-12-01). "Dopamine regulation in schizotypal personality disorder and psychosis". Current Psychosis & Therapeutics Reports. 3 (4): 162–168. doi:10.1007/BF02629449. ISSN   1545-8091. S2CID   144051452 – via SpringerLink.
  82. ↑ Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV (June 2004). "Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction". Psychopharmacology. 174 (1): 3–16. doi:10.1007/s00213-004-1793-y. PMID   15118803. S2CID   25015952.
  83. ↑ Kirschner M, Hager OM, Muff L, Bischof M, Hartmann-Riemer MN, Kluge A, et al. (January 2018). "Ventral Striatal Dysfunction and Symptom Expression in Individuals With Schizotypal Personality Traits and Early Psychosis". Schizophrenia Bulletin. 44 (1): 147–157. doi:10.1093/schbul/sbw142. PMC   5767950 . PMID   27798223.
  84. ↑ Waltmann M, O'Daly O, Egerton A, McMullen K, Kumari V, Barker GJ, et al. (2019-01-01). "Multi-echo fMRI, resting-state connectivity, and high psychometric schizotypy". NeuroImage. Clinical. 21: 101603. doi:10.1016/j.nicl.2018.11.013. PMC   6413302 . PMID   30503214. S2CID   53873865.
  85. ↑ Siever LJ, Davis KL (2004-03-01). "The Pathophysiology of Schizophrenia Disorders: Perspectives From the Spectrum". American Journal of Psychiatry. 161 (3): 398–413. doi:10.1176/appi.ajp.161.3.398. PMID   14992962.
  86. ↑ Rössler J, Unterassner L, Wyss T, Haker H, Brugger P, Rössler W, et al. (April 2019). "Schizotypal Traits are Linked to Dopamine-Induced Striato-Cortical Decoupling: A Randomized Double-Blind Placebo-Controlled Study". Schizophrenia Bulletin. 45 (3): 680–688. doi:10.1093/schbul/sby079. PMC   6483584 . PMID   29878280.
  87. ↑ Miyake N, Thompson J, Skinbjerg M, Abi-Dargham A (April 2011). "Presynaptic dopamine in schizophrenia". CNS Neuroscience & Therapeutics. 17 (2): 104–109. doi:10.1111/j.1755-5949.2010.00230.x. PMC   6493810 . PMID   21199451.
  88. ↑ Fervaha G, Remington G (June 2013). "Neuroimaging findings in schizotypal personality disorder: a systematic review". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 43: 96–107. doi:10.1016/j.pnpbp.2012.11.014. PMID   23220094. S2CID   25236324.
  89. ↑ Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, et al. (December 2011). "Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study". The American Journal of Psychiatry. 168 (12): 1311–1317. doi:10.1176/appi.ajp.2011.11010160. PMC   3682447 . PMID   21768612.
  90. ↑ Egerton A, Chaddock CA, Winton-Brown TT, Bloomfield MA, Bhattacharyya S, Allen P, et al. (July 2013). "Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort". Biological Psychiatry. Corticostriatal Networks, Psychopathology, and Treatment. 74 (2): 106–112. doi:10.1016/j.biopsych.2012.11.017. PMID   23312565. S2CID   25232879.
  91. ↑ Levitt JJ, Westin CF, Nestor PG, Estepar RS, Dickey CC, Voglmaier MM, et al. (January 2004). "Shape of caudate nucleus and its cognitive correlates in neuroleptic-naive schizotypal personality disorder". Biological Psychiatry. 55 (2): 177–184. doi:10.1016/j.biopsych.2003.08.005. PMC   2793335 . PMID   14732598.
  92. ↑ Haidar H, Bouix S, Levitt JJ, McCarley RW, Shenton ME, Soul JS (October 2006). "Characterizing the shape of anatomical structures with Poisson's equation". IEEE Transactions on Medical Imaging. 25 (10): 1249–1257. doi:10.1109/TMI.2006.881378. PMC   2785042 . PMID   17024829.
  93. ↑ Niethammer M, Reuter M, Wolter FE, Bouix S, Peinecke N, Koo MS, et al. (2007). Global Medical Shape Analysis Using the Laplace-Beltrami Spectrum. Medical Image Computing and Computer-Assisted Intervention – MICCAI 2007. Lecture Notes in Computer Science. Vol. 4791. pp. 850–857. doi:10.1007/978-3-540-75757-3_103. ISBN   978-3-540-75756-6. PMC   2782516 . PMID   18051138.
  94. ↑ Koo MS, Levitt JJ, McCarley RW, Seidman LJ, Dickey CC, Niznikiewicz MA, et al. (July 2006). "Reduction of caudate nucleus volumes in neuroleptic-naïve female subjects with schizotypal personality disorder". Biological Psychiatry. 60 (1): 40–48. doi:10.1016/j.biopsych.2005.09.028. PMC   2768064 . PMID   16460694.
  95. ↑ Levitt JJ, Styner M, Niethammer M, Bouix S, Koo MS, Voglmaier MM, et al. (May 2009). "Shape abnormalities of caudate nucleus in schizotypal personality disorder". Schizophrenia Research. 110 (1–3): 127–139. doi:10.1016/j.schres.2008.11.012. PMC   2756791 . PMID   19328654.
  96. ↑ Levitt JJ, McCarley RW, Dickey CC, Voglmaier MM, Niznikiewicz MA, Seidman LJ, et al. (July 2002). "MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder". The American Journal of Psychiatry. 159 (7): 1190–1197. doi:10.1176/appi.ajp.159.7.1190. PMC   2826363 . PMID   12091198.
  97. ↑ Dickey CC, McCarley RW, Voglmaier MM, Niznikiewicz MA, Seidman LJ, Hirayasu Y, et al. (June 1999). "Schizotypal personality disorder and MRI abnormalities of temporal lobe gray matter". Biological Psychiatry. 45 (11): 1393–1402. doi:10.1016/S0006-3223(99)00030-X. PMC   2832794 . PMID   10356620. S2CID   9398471.
  98. ↑ Zhu Y, Tang Y, Zhang T, Li H, Tang Y, Li C, et al. (February 2017). "Reduced functional connectivity between bilateral precuneus and contralateral parahippocampus in schizotypal personality disorder". BMC Psychiatry. 17 (1): 48. doi: 10.1186/s12888-016-1146-5 . PMC   5288938 . PMID   28152990.
  99. ↑ Dickey CC, Shenton ME, Hirayasu Y, Fischer I, Voglmaier MM, Niznikiewicz MA, et al. (January 2000). "Large CSF volume not attributable to ventricular volume in schizotypal personality disorder". The American Journal of Psychiatry. 157 (1): 48–54. doi:10.1176/ajp.157.1.48. PMC   2832789 . PMID   10618012.
  100. ↑ Asami T, Whitford TJ, Bouix S, Dickey CC, Niznikiewicz M, Shenton ME, et al. (April 2013). "Globally and locally reduced MRI gray matter volumes in neuroleptic-naive men with schizotypal personality disorder: association with negative symptoms". JAMA Psychiatry. 70 (4): 361–372. doi: 10.1001/jamapsychiatry.2013.665 . PMID   23389420.
  101. ↑ Dickey CC, McCarley RW, Voglmaier MM, Frumin M, Niznikiewicz MA, Hirayasu Y, et al. (September 2002). "Smaller left Heschl's gyrus volume in patients with schizotypal personality disorder". The American Journal of Psychiatry. 159 (9): 1521–1527. doi:10.1176/appi.ajp.159.9.1521. PMC   2832788 . PMID   12202272.
  102. ↑ Dickey CC, McCarley RW, Voglmaier MM, Niznikiewicz MA, Seidman LJ, Frumin M, et al. (November 2003). "A MRI study of fusiform gyrus in schizotypal personality disorder". Schizophrenia Research. 64 (1): 35–39. doi:10.1016/S0920-9964(02)00529-7. PMC   2848253 . PMID   14511799. S2CID   8218211.
  103. ↑ Lener MS, Wong E, Tang CY, Byne W, Goldstein KE, Blair NJ, et al. (January 2015). "White matter abnormalities in schizophrenia and schizotypal personality disorder". Schizophrenia Bulletin. 41 (1): 300–310. doi:10.1093/schbul/sbu093. PMC   4266294 . PMID   24962608.
  104. ↑ Dickey CC, McCarley RW, Shenton ME (2002). "The brain in schizotypal personality disorder: a review of structural MRI and CT findings". Harvard Review of Psychiatry. 10 (1): 1–15. doi:10.1080/10673220216201. PMC   2854016 . PMID   11751641.
  105. ↑ Goldstein KE, Hazlett EA, New AS, Haznedar MM, Newmark RE, Zelmanova Y, et al. (July 2009). "Smaller superior temporal gyrus volume specificity in schizotypal personality disorder". Schizophrenia Research. 112 (1–3): 14–23. doi:10.1016/j.schres.2009.04.027. PMC   2782902 . PMID   19473820.
  106. ↑ Takayanagi Y, Sasabayashi D, Takahashi T, Furuichi A, Kido M, Nishikawa Y, et al. (February 2020). "Reduced Cortical Thickness in Schizophrenia and Schizotypal Disorder". Schizophrenia Bulletin. 46 (2): 387–394. doi:10.1093/schbul/sbz051. PMC   7406196 . PMID   31167030.
  107. ↑ Perez-Rodriguez MM, Zaluda L, New AS (April 2013). "Biological Advances in Personality Disorders". FOCUS. 11 (2): 146–154. doi:10.1176/appi.focus.11.2.146. ISSN   1541-4094.
  108. ↑ Hazlett EA, Collazo T, Zelmanova Y, Entis JJ, Chu KW, Goldstein KE, et al. (November 2012). "Anterior limb of the internal capsule in schizotypal personality disorder: fiber-tract counting, volume, and anisotropy". Schizophrenia Research. 141 (2–3): 119–127. doi:10.1016/j.schres.2012.08.022. PMC   3742803 . PMID   22995934.
  109. ↑ Suzuki M, Zhou SY, Hagino H, Takahashi T, Kawasaki Y, Nohara S, et al. (April 2004). "Volume reduction of the right anterior limb of the internal capsule in patients with schizotypal disorder". Psychiatry Research. 130 (3): 213–225. doi:10.1016/j.pscychresns.2004.01.001. PMID   15135156. S2CID   40481295.
  110. ↑ Hazlett EA, Goldstein KE, Kolaitis JC (February 2012). "A review of structural MRI and diffusion tensor imaging in schizotypal personality disorder". Current Psychiatry Reports. 14 (1): 70–78. doi:10.1007/s11920-011-0241-z. PMC   3256320 . PMID   22006127.
  111. ↑ Hazlett EA, Goldstein KE, Tajima-Pozo K, Speidel ER, Zelmanova Y, Entis JJ, et al. (April 2011). "Cingulate and temporal lobe fractional anisotropy in schizotypal personality disorder". NeuroImage. 55 (3): 900–908. doi:10.1016/j.neuroimage.2010.12.082. PMC   3262398 . PMID   21223999.
  112. ↑ Gurrera RJ, Nakamura M, Kubicki M, Dickey CC, Niznikiewicz MA, Voglmaier MM, et al. (February 2007). "The uncinate fasciculus and extraversion in schizotypal personality disorder: a diffusion tensor imaging study". Schizophrenia Research. 90 (1–3): 360–362. doi:10.1016/j.schres.2006.10.003. PMC   1876710 . PMID   17126532.
  113. 1 2 Lagioia A, Eliez S, Schneider M, Simons JS, Van der Linden M, Debbané M (April 2011). "Neural correlates of reality monitoring during adolescence" (PDF). NeuroImage. 55 (3): 1393–1400. doi:10.1016/j.neuroimage.2010.12.058. PMID   21195192. S2CID   757306.
  114. ↑ Liu K, Zhang T, Zhang Q, Sun Y, Wu J, Lei Y, et al. (2016). "Characterization of the Fiber Connectivity Profile of the Cerebral Cortex in Schizotypal Personality Disorder: A Pilot Study". Frontiers in Psychology. 7: 809. doi: 10.3389/fpsyg.2016.00809 . PMC   4884735 . PMID   27303358.
  115. ↑ Sasabayashi D, Takayanagi Y, Takahashi T, Nemoto K, Furuichi A, Kido M, et al. (January 2020). "Increased brain gyrification in the schizophrenia spectrum". Psychiatry and Clinical Neurosciences. 74 (1): 70–76. doi: 10.1111/pcn.12939 . PMID   31596011. S2CID   203985518.
  116. ↑ Hazlett EA, Buchsbaum MS, Haznedar MM, Newmark R, Goldstein KE, Zelmanova Y, et al. (April 2008). "Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients". Schizophrenia Research. 101 (1–3): 111–123. doi:10.1016/j.schres.2007.12.472. PMC   2672563 . PMID   18272348. S2CID   12723481.
  117. ↑ Perez-Rodriguez MM, New AS, Goldstein KE, Rosell D, Yuan Q, Zhou Z, et al. (May 2017). "Brain-derived neurotrophic factor Val66Met genotype modulates amygdala habituation". Psychiatry Research: Neuroimaging. 263: 85–92. doi:10.1016/j.pscychresns.2017.03.008. PMC   5856456 . PMID   28371657.
  118. ↑ Stanfield AC, Philip RC, Whalley H, Romaniuk L, Hall J, Johnstone EC, et al. (October 2017). "Dissociation of Brain Activation in Autism and Schizotypal Personality Disorder During Social Judgments". Schizophrenia Bulletin. 43 (6): 1220–1228. doi:10.1093/schbul/sbx083. PMC   5737648 . PMID   29088456.
  119. ↑ Chemerinski E, Byne W, Kolaitis JC, Glanton CF, Canfield EL, Newmark RE, et al. (January 2013). "Larger putamen size in antipsychotic-naïve individuals with schizotypal personality disorder". Schizophrenia Research. 143 (1): 158–164. doi:10.1016/j.schres.2012.11.003. PMC   3634353 . PMID   23187070.
  120. ↑ Romo-Nava F, Hoogenboom WS, Pelavin PE, Alvarado JL, Bobrow LH, Macmaster FP, et al. (May 2013). "Pituitary volume in schizophrenia spectrum disorders". Schizophrenia Research. 146 (1–3): 301–307. doi:10.1016/j.schres.2013.02.024. PMC   3760333 . PMID   23522905.
  121. ↑ Cadenhead KS, Light GA, Geyer MA, McDowell JE, Braff DL (May 2002). "Neurobiological measures of schizotypal personality disorder: defining an inhibitory endophenotype?". The American Journal of Psychiatry. 159 (5): 869–871. doi:10.1176/appi.ajp.159.5.869. PMID   11986147.
  122. ↑ Hazlett EA, Levine J, Buchsbaum MS, Silverman JM, New A, Sevin EM, et al. (September 2003). "Deficient attentional modulation of the startle response in patients with schizotypal personality disorder". The American Journal of Psychiatry. 160 (9): 1621–1626. doi:10.1176/appi.ajp.160.9.1621. PMID   12944337.
  123. ↑ Cadenhead KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL (October 2000). "Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits". The American Journal of Psychiatry. 157 (10): 1660–1668. doi:10.1176/appi.ajp.157.10.1660. PMID   11007721.
  124. ↑ Cadenhead KS, Geyer MA, Braff DL (December 1993). "Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder". The American Journal of Psychiatry. 150 (12): 1862–1867. doi:10.1176/ajp.150.12.1862. PMID   8238643.
  125. ↑ Siever LJ, Amin F, Coccaro EF, Trestman R, Silverman J, Horvath TB, et al. (January 1993). "CSF homovanillic acid in schizotypal personality disorder". The American Journal of Psychiatry. 150 (1): 149–151. doi:10.1176/ajp.150.1.149. PMID   8417559.
  126. ↑ Kwon JS, Shenton ME, Hirayasu Y, Salisbury DF, Fischer IA, Dickey CC, et al. (April 1998). "MRI study of cavum septi pellucidi in schizophrenia, affective disorder, and schizotypal personality disorder". The American Journal of Psychiatry. 155 (4): 509–515. doi:10.1176/ajp.155.4.509. PMC   2826366 . PMID   9545997.
  127. ↑ Anglin DM, Corcoran CM, Brown AS, Chen H, Lighty Q, Brook JS, et al. (May 2012). "Early cannabis use and schizotypal personality disorder symptoms from adolescence to middle adulthood". Schizophrenia Research. 137 (1–3): 45–49. doi:10.1016/j.schres.2012.01.019. PMC   3591468 . PMID   22325079.
  128. ↑ Davis GP, Compton MT, Wang S, Levin FR, Blanco C (December 2013). "Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions". Schizophrenia Research. 151 (1–3): 197–202. doi:10.1016/j.schres.2013.10.018. PMC   3877688 . PMID   24200416.
  129. ↑ Hjorthøj C, Albert N, Nordentoft M (July 2018). "Association of Substance Use Disorders With Conversion From Schizotypal Disorder to Schizophrenia". JAMA Psychiatry. 75 (7): 733–739. doi:10.1001/jamapsychiatry.2018.0568. PMC   6145672 . PMID   29710317. S2CID   13966874.
  130. ↑ Fridberg DJ, Vollmer JM, O'Donnell BF, Skosnik PD (March 2011). "Cannabis users differ from non-users on measures of personality and schizotypy". Psychiatry Research. 186 (1): 46–52. doi:10.1016/j.psychres.2010.07.035. PMC   3036782 . PMID   20813412.
  131. ↑ Dong F, Liu J, Hodgson NA, Medoff-Cooper B (December 2021). "Early life factors of schizotypal personality disorder in adolescents: A systematic review". Journal of Psychiatric and Mental Health Nursing. 28 (6): 1092–1112. doi:10.1111/jpm.12733. PMID   33502097. S2CID   231761157.
  132. ↑ Deidre M. Anglina, Patricia R. Cohenab, Henian Chena (2008) Duration of early maternal separation and prediction of schizotypal symptoms from early adolescence to midlife, Schizophrenia Research Volume 103, Issue 1, Pages 143–150 (August 2008)
  133. ↑ Howard Berenbaum, Ph.D., Eve M. Valera, Ph.D. and John G. Kerns, Ph.D. (2003) Psychological Trauma and Schizotypal Symptoms, Oxford Journals, Medicine, Schizophrenia Bulletin Volume 29, Number 1 Pp. 143–152
  134. ↑ Tessner KD, Mittal V, Walker EF (March 2011). "Longitudinal study of stressful life events and daily stressors among adolescents at high risk for psychotic disorders". Schizophrenia Bulletin. 37 (2): 432–441. doi:10.1093/schbul/sbp087. PMC   3044629 . PMID   19734244.
  135. ↑ Liu J, Gong J, Nie G, He Y, Xiao B, Shen Y, et al. (October 2017). "The mediating effects of childhood neglect on the association between schizotypal and autistic personality traits and depression in a non-clinical sample". BMC Psychiatry. 17 (1): 352. doi: 10.1186/s12888-017-1510-0 . PMC   5655952 . PMID   29065890.
  136. ↑ Anglin DM, Cohen PR, Chen H (August 2008). "Duration of early maternal separation and prediction of schizotypal symptoms from early adolescence to midlife". Schizophrenia Research. 103 (1–3): 143–150. doi:10.1016/j.schres.2008.02.016. PMC   2603441 . PMID   18407465.
  137. ↑ Berenbaum H, Thompson RJ, Milanek ME, Boden MT, Bredemeier K (August 2008). "Psychological trauma and schizotypal personality disorder". Journal of Abnormal Psychology. 117 (3): 502–519. doi:10.1037/0021-843X.117.3.502. PMID   18729605.
  138. 1 2 Lentz V, Robinson J, Bolton JM (November 2010). "Childhood adversity, mental disorder comorbidity, and suicidal behavior in schizotypal personality disorder". The Journal of Nervous and Mental Disease. 198 (11): 795–801. doi:10.1097/NMD.0b013e3181f9804c. PMID   21048469. S2CID   205882039.
  139. ↑ Ericson M, Tuvblad C, Raine A, Young-Wolff K, Baker LA (July 2011). "Heritability and longitudinal stability of schizotypal traits during adolescence". Behavior Genetics. 41 (4): 499–511. doi:10.1007/s10519-010-9401-x. PMC   3123391 . PMID   21369821.
  140. ↑ Wong KK, Raine A (2018-03-01). "Developmental Aspects of Schizotypy and Suspiciousness: a Review". Current Behavioral Neuroscience Reports. 5 (1): 94–101. doi:10.1007/s40473-018-0144-y. PMC   5857559 . PMID   29577010.
  141. ↑ Machón RA, Huttunen MO, Mednick SA, Sinivuo J, Tanskanen A, Bunn Watson J, et al. (March 2002). "Adult schizotypal personality characteristics and prenatal influenza in a Finnish birth cohort". Schizophrenia Research. 54 (1–2): 7–16. doi:10.1016/S0920-9964(01)00346-2. PMID   11853973. S2CID   20875584.
  142. ↑ Mayo Clinic Staff. "Schizotypal personality disorder". Mayo Clinic. Archived from the original on 9 March 2012. Retrieved 21 February 2012.
  143. ↑ Dizinger JM, Doll CM, Rosen M, Gruen M, Daum L, Schultze-Lutter F, et al. (August 2022). "Does childhood trauma predict schizotypal traits? A path modelling approach in a cohort of help-seeking subjects". European Archives of Psychiatry and Clinical Neuroscience. 272 (5): 909–922. doi:10.1007/s00406-021-01373-6. PMC   9279245 . PMID   34982217.
  144. 1 2 Powers AD, Thomas KM, Ressler KJ, Bradley B (2011-07-01). "The differential effects of child abuse and posttraumatic stress disorder on schizotypal personality disorder". Comprehensive Psychiatry. 52 (4): 438–445. doi:10.1016/j.comppsych.2010.08.001. PMC   3122145 . PMID   21683181.
  145. ↑ Cohen P, Chen H, Gordon K, Johnson J, Brook J, Kasen S (2008). "Socioeconomic background and the developmental course of schizotypal and borderline personality disorder symptoms". Development and Psychopathology. 20 (2): 633–650. doi:10.1017/S095457940800031X. PMC   3857688 . PMID   18423098.
  146. ↑ Velikonja T, Velthorst E, McClure MM, Rutter S, Calabrese WR, Rosell D, et al. (July 2019). "Severe childhood trauma and clinical and neurocognitive features in schizotypal personality disorder". Acta Psychiatrica Scandinavica. 140 (1): 50–64. doi:10.1111/acps.13032. PMID   30951190. S2CID   96436653.
  147. 1 2 Roitman SE, Cornblatt BA, Bergman A, Obuchowski M, Mitropoulou V, Keefe RS, et al. (May 1997). "Attentional functioning in schizotypal personality disorder". The American Journal of Psychiatry. 154 (5): 655–660. doi:10.1176/ajp.154.5.655. PMID   9137121.
  148. ↑ Esterberg ML, Goulding SM, Walker EF (December 2010). "Cluster A Personality Disorders: Schizotypal, Schizoid and Paranoid Personality Disorders in Childhood and Adolescence". Journal of Psychopathology and Behavioral Assessment. 32 (4): 515–528. doi:10.1007/s10862-010-9183-8. PMC   2992453 . PMID   21116455.
  149. ↑ Olin SS, Raine A, Cannon TD, Parnas J, Schulsinger F, Mednick SA (1997). "Childhood behavior precursors of schizotypal personality disorder". Schizophrenia Bulletin. 23 (1): 93–103. doi: 10.1093/schbul/23.1.93 . PMID   9050116.
  150. ↑ Raine A, Wong KK, Liu J (March 2021). "The Schizotypal Personality Questionnaire for Children (SPQ-C): Factor Structure, Child Abuse, and Family History of Schizotypy". Schizophrenia Bulletin. 47 (2): 323–331. doi:10.1093/schbul/sbaa100. PMC   8370046 . PMID   32674122.
  151. ↑ Berenbaum H, Valera EM, Kerns JG (2003). "Psychological trauma and schizotypal symptoms". Schizophrenia Bulletin. 29 (1): 143–152. doi: 10.1093/oxfordjournals.schbul.a006985 . PMID   12908670.
  152. ↑ Fonseca-Pedrero E, Ortuño J, Debbané M, Chan RC, Cicero D, Zhang LC, et al. (October 2018). "The Network Structure of Schizotypal Personality Traits". Schizophrenia Bulletin. 44 (suppl_2): S468–S479. doi:10.1093/schbul/sby044. PMC   6188518 . PMID   29684178.
  153. ↑ Davidson CA, Hoffman L, Spaulding WD (April 2016). "Schizotypal personality questionnaire--brief revised (updated): An update of norms, factor structure, and item content in a large non-clinical young adult sample". Psychiatry Research. 238: 345–355. doi:10.1016/j.psychres.2016.01.053. PMC   4834869 . PMID   27086255.
  154. ↑ Sokolova E, Andreyuk K, Ryzhov A (2021). "Relationship of abstract thinking to mentalization in schizophrenia". European Psychiatry. 64 (S1): S527. doi:10.1192/j.eurpsy.2021.1407. ISSN   0924-9338. PMC   9475916 .
  155. ↑ Crespi B, Dinsdale N, Read S, Hurd P (2019-03-08). "Spirituality, dimensional autism, and schizotypal traits: The search for meaning". PLOS ONE. 14 (3): e0213456. Bibcode:2019PLoSO..1413456C. doi: 10.1371/journal.pone.0213456 . PMC   6407781 . PMID   30849096.
  156. ↑ Carvalho LF, Sagradim DE, Pianowski G, Gonçalves AP (2020-10-19). "Relationship between religiosity domains and traits from borderline and schizotypal personality disorders in a Brazilian community sample". Trends in Psychiatry and Psychotherapy. 42 (3): 239–246. doi:10.1590/2237-6089-2019-0085. PMC   7879071 . PMID   33084801. S2CID   224828232.
  157. ↑ Breslin MJ, Lewis CA (2015-03-04). "Schizotypy and Religiosity: The Magic of Prayer". Archive for the Psychology of Religion. 37 (1): 84–97. doi:10.1163/15736121-12341300. ISSN   0084-6724. S2CID   144734469.
  158. ↑ Byrom GN (2009). "Differential Relationships between Experiential and Interpretive Dimensions of Mysticism and Schizotypal Magical Ideation in a University Sample". Archive for the Psychology of Religion. 31 (2): 127–150. doi:10.1163/157361209X424420. ISSN   0084-6724. S2CID   143580864.
  159. ↑ Farsham A, Abbaslou T, Bidaki R, Bozorg B (April 2017). "Comparing Facial Emotional Recognition in Patients with Borderline Personality Disorder and Patients with Schizotypal Personality Disorder with a Normal Group". Iranian Journal of Psychiatry. 12 (2): 87–92. PMC   5483242 . PMID   28659980.
  160. ↑ Dickey CC, McCarley RW, Niznikiewicz MA, Voglmaier MM, Seidman LJ, Kim S, et al. (October 2005). "Clinical, cognitive, and social characteristics of a sample of neuroleptic-naive persons with schizotypal personality disorder". Schizophrenia Research. 78 (2–3): 297–308. doi:10.1016/j.schres.2005.05.016. PMC   2766931 . PMID   15985362.
  161. ↑ Wong KK, Raine A (2020-09-18). "Schizotypal Personality Disorder". In Carducci BJ, Nave CS, Mio JS, Riggio RE (eds.). The Wiley Encyclopedia of Personality and Individual Differences (1st ed.). Wiley. pp. 115–120. doi:10.1002/9781118970843.ch283. ISBN   978-1-118-97074-4.
  162. ↑ Hummelen B, Pedersen G, Karterud S (May 2012). "Some suggestions for the DSM-5 schizotypal personality disorder construct". Comprehensive Psychiatry. 53 (4): 341–349. doi:10.1016/j.comppsych.2011.05.009. PMID   21741634.
  163. ↑ Chan CC, Bulbena-Cabre A, Rutter S, Benavides C, McClure MM, Calabrese W, et al. (July 2019). "Comparison of self-report and clinician-rated schizotypal traits in schizotypal personality disorder and community controls". Schizophrenia Research. 209: 263–268. doi:10.1016/j.schres.2018.12.050. PMC   6614007 . PMID   30635257.
  164. ↑ Pattamanusorn N, Wongpakaran N, Thongpibul K, Wongpakaran T, Kuntawong P (May 2020). "Pathogenic beliefs among patients with schizotypal personality disorder". Heliyon. 6 (5): e03870. Bibcode:2020Heliy...603870P. doi:10.1016/j.heliyon.2020.e03870. PMC   7200782 . PMID   32382682. S2CID   218555815.
  165. ↑ Raballo A, Poletti M, Preti A, Parnas J (July 2021). "The Self in the Spectrum: A Meta-analysis of the Evidence Linking Basic Self-Disorders and Schizophrenia". Schizophrenia Bulletin. 47 (4): 1007–1017. doi:10.1093/schbul/sbaa201. PMC   8266610 . PMID   33479736.
  166. ↑ Carlson EN, Oltmanns TF (August 2015). "The Role of Metaperception in Personality Disorders: Do People with Personality Problems Know How Others Experience Their Personality?". Journal of Personality Disorders. 29 (4): 449–467. doi:10.1521/pedi.2015.29.4.449. PMC   4760634 . PMID   26200846.
  167. ↑ Dickey CC, Panych LP, Voglmaier MM, Niznikiewicz MA, Terry DP, Murphy C, et al. (September 2011). "Facial emotion recognition and facial affect display in schizotypal personality disorder". Schizophrenia Research. 131 (1–3): 242–249. doi:10.1016/j.schres.2011.04.020. PMC   3159849 . PMID   21640557.
  168. ↑ Thakkar KN, Park S (September 2010). "Empathy, schizotypy, and visuospatial transformations". Cognitive Neuropsychiatry. 15 (5): 477–500. doi:10.1080/13546801003711350. PMC   2933940 . PMID   20437282.
  169. ↑ Dickey CC, Vu MA, Voglmaier MM, Niznikiewicz MA, McCarley RW, Panych LP (December 2012). "Prosodic abnormalities in schizotypal personality disorder". Schizophrenia Research. 142 (1–3): 20–30. doi:10.1016/j.schres.2012.09.006. PMC   3502641 . PMID   23068317.
  170. ↑ Phillips LK, Seidman LJ (September 2008). "Emotion processing in persons at risk for schizophrenia". Schizophrenia Bulletin. 34 (5): 888–903. doi:10.1093/schbul/sbn085. PMC   2518637 . PMID   18644853.
  171. ↑ van 't Wout M, Sanfey AG (January 2011). "Interactive decision-making in people with schizotypal traits: a game theory approach". Psychiatry Research. 185 (1–2): 92–96. doi:10.1016/j.psychres.2010.05.013. PMC   2943544 . PMID   20538347.
  172. ↑ Shi YF, Wang Y, Cao XY, Wang Y, Wang YN, Zong JG, et al. (2012-05-16). "Experience of pleasure and emotional expression in individuals with schizotypal personality features". PLOS ONE. 7 (5): e34147. Bibcode:2012PLoSO...734147S. doi: 10.1371/journal.pone.0034147 . PMC   3353966 . PMID   22615731.
  173. ↑ Yan C, Liu WH, Cao Y, Chan RC (September 2011). "Self-reported pleasure experience and motivation in individuals with schizotypal personality disorders proneness". East Asian Archives of Psychiatry. 21 (3): 115–122. PMID   21921305.
  174. ↑ Horan WP, Blanchard JJ, Clark LA, Green MF (September 2008). "Affective traits in schizophrenia and schizotypy". Schizophrenia Bulletin. 34 (5): 856–874. doi:10.1093/schbul/sbn083. PMC   2632479 . PMID   18667393.
  175. ↑ Geng FL, Xu T, Wang Y, Shi HS, Yan C, Neumann DL, et al. (November 2013). "Developmental trajectories of schizotypal personality disorder-like behavioural manifestations: a two-year longitudinal prospective study of college students". BMC Psychiatry. 13 (1): 323. doi: 10.1186/1471-244X-13-323 . PMC   3875349 . PMID   24289659.
  176. ↑ Blanchard JJ, Aghevli M, Wilson A, Sargeant M (May 2010). "Developmental instability in social anhedonia: an examination of minor physical anomalies and clinical characteristics". Schizophrenia Research. 118 (1–3): 162–167. doi:10.1016/j.schres.2009.10.028. PMC   2856752 . PMID   19944570.
  177. ↑ Vinogradova M, Chepeliuk A, Dorofeeva O (2021). "Productivity of the performance of visual perceptual tasks and symptom severity in patients with schizotypal disorder". European Psychiatry. 64 (S1): S525. doi:10.1192/j.eurpsy.2021.1402. ISSN   0924-9338. PMC   9476036 .
  178. ↑ Mittal VA, Tessner KD, Walker EF (August 2007). "Elevated social Internet use and schizotypal personality disorder in adolescents". Schizophrenia Research. 94 (1–3): 50–57. doi:10.1016/j.schres.2007.04.009. PMC   2323598 . PMID   17532188.
  179. ↑ de Francisco Carvalho L, Magarotto Machado G, Padovani S, Pianowski G (December 2021). "Measuring pathological traits of the schizotypal personality disorder through the HiTOP model". Scandinavian Journal of Psychology. 62 (6): 839–845. doi:10.1111/sjop.12761. PMID   34245006. S2CID   235786787.
  180. ↑ Hamilton HK, Simeon D (2018-12-27), Moskowitz A, Dorahy MJ, Schäfer I (eds.), "Depersonalization/Derealization Disorder and Schizotypal Personality Disorder", Psychosis, Trauma and Dissociation (1st ed.), Wiley, pp. 241–256, doi:10.1002/9781118585948.ch15, ISBN   978-1-119-95285-5, S2CID   149618564 , retrieved 2022-10-29
  181. ↑ Hamilton H, Simeon D (November 19, 2018). "Depersonalization/Derealization Disorder and Schizotypal Personality Disorder". Psychosis, Trauma and Dissociation: Evolving Perspectives on Severe Psychopathology. Wiley. pp. 241–256. doi:10.1002/9781118585948.ch15. ISBN   978-1-119-95285-5. S2CID   149618564.
  182. ↑ Zandersen M, Parnas J (January 2019). "Identity Disturbance, Feelings of Emptiness, and the Boundaries of the Schizophrenia Spectrum". Schizophrenia Bulletin. 45 (1): 106–113. doi:10.1093/schbul/sbx183. PMC   6293220 . PMID   29373752.
  183. ↑ Siever LJ, Coursey RD, Alterman IS, Buchsbaum MS, Murphy DL (December 1984). "Impaired smooth pursuit eye movement: vulnerability marker for schizotypal personality disorder in a normal volunteer population". The American Journal of Psychiatry. 141 (12): 1560–1566. doi:10.1176/ajp.141.12.1560. PMID   6507660.
  184. ↑ Hazlett EA, Buchsbaum MS, Zhang J, Newmark RE, Glanton CF, Zelmanova Y, et al. (September 2008). "Frontal-striatal-thalamic mediodorsal nucleus dysfunction in schizophrenia-spectrum patients during sensorimotor gating". NeuroImage. 42 (3): 1164–1177. doi:10.1016/j.neuroimage.2008.05.039. PMC   2548278 . PMID   18588988.
  185. ↑ Siever LJ, Keefe R, Bernstein DP, Coccaro EF, Klar HM, Zemishlany Z, et al. (June 1990). "Eye tracking impairment in clinically identified patients with schizotypal personality disorder". The American Journal of Psychiatry. 147 (6): 740–745. doi:10.1176/ajp.147.6.740. PMID   2343917.
  186. ↑ Siever LJ, Friedman L, Moskowitz J, Mitropoulou V, Keefe R, Roitman SL, et al. (August 1994). "Eye movement impairment and schizotypal psychopathology". The American Journal of Psychiatry. 151 (8): 1209–1215. doi:10.1176/ajp.151.8.1209. PMID   8037257.
  187. 1 2 Cadenhead KS, Light GA, Geyer MA, Braff DL (January 2000). "Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder". The American Journal of Psychiatry. 157 (1): 55–59. doi:10.1176/ajp.157.1.55. PMID   10618013. S2CID   20139616.
  188. ↑ Raballo A, Parnas J (September 2011). "The silent side of the spectrum: schizotypy and the schizotaxic self". Schizophrenia Bulletin. 37 (5): 1017–1026. doi:10.1093/schbul/sbq008. PMC   3160219 . PMID   20176859.
  189. ↑ Fenton WS, McGlashan TH, Victor BJ, Blyler CR (February 1997). "Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders". The American Journal of Psychiatry. 154 (2): 199–204. doi:10.1176/ajp.154.2.199. PMID   9016268. S2CID   33964324.
  190. ↑ Weiser M, Noy S, Kaplan Z, Reichenberg A, Yazvitsky R, Nahon D, et al. (January 2003). "Generalized cognitive impairment in male adolescents with schizotypal personality disorder". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 116B (1): 36–40. doi:10.1002/ajmg.b.10853. PMID   12497611. S2CID   24719039.
  191. ↑ Hazlett EA, Rothstein EG, Ferreira R, Silverman JM, Siever LJ, Olincy A (February 2015). "Sensory gating disturbances in the spectrum: similarities and differences in schizotypal personality disorder and schizophrenia". Schizophrenia Research. 161 (2–3): 283–290. doi:10.1016/j.schres.2014.11.020. PMC   4308515 . PMID   25482574.
  192. ↑ Cohen AS, Auster TL, MacAulay RK, McGovern JE (October 2014). "Illusory superiority and schizotypal personality: explaining the discrepancy between subjective/objective psychopathology". Personality Disorders. 5 (4): 413–418. doi:10.1037/per0000080. PMC   4372844 . PMID   25150366.
  193. 1 2 Fonseca-Pedrero E, Badoud D, Antico L, Caputo GB, Eliez S, Schwartz S, et al. (March 2015). "Strange-face-in-the-mirror illusion and schizotypy during adolescence". Schizophrenia Bulletin. 41 (Suppl 2): S475–S482. doi:10.1093/schbul/sbu196. PMC   4373638 . PMID   25810060.
  194. ↑ Leonards U, Mohr C (September 2009). "Schizotypal personality traits influence idiosyncratic initiation of saccadic face exploration". Vision Research. 49 (19): 2404–2413. doi:10.1016/j.visres.2009.07.013. PMID   19643123. S2CID   16477946.
  195. ↑ Ahn S, Lustenberger C, Jarskog LF, Fröhlich F (February 2020). "Neurophysiological substrates of configural face perception in schizotypy". Schizophrenia Research. 216: 389–396. doi:10.1016/j.schres.2019.11.005. PMC   7239709 . PMID   31801677.
  196. ↑ Terrien S, Gobin P, Iakimova G, Coutté A, Thuaire F, Baltazart V, et al. (March 2016). "Electrophysiological correlates of emotional meaning in context in relation to facets of schizotypal personality traits: A dimensional study". Psychiatry and Clinical Neurosciences. 70 (3): 141–150. doi: 10.1111/pcn.12366 . PMID   26482112. S2CID   206256765.
  197. ↑ Mitropoulou V, Harvey PD, Zegarelli G, New AS, Silverman JM, Siever LJ (October 2005). "Neuropsychological performance in schizotypal personality disorder: importance of working memory". The American Journal of Psychiatry. 162 (10): 1896–1903. doi:10.1176/appi.ajp.162.10.1896. PMID   16199836.
  198. ↑ Rabella M, Grasa E, Corripio I, Romero S, Mañanas MÀ, Antonijoan RM, et al. (2016-01-01). "Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism". NeuroImage. Clinical. 11: 770–779. doi:10.1016/j.nicl.2016.05.019. PMC   4909819 . PMID   27330977. S2CID   14043730.
  199. ↑ Niznikiewicz MA, Spencer KM, Dickey C, Voglmaier M, Seidman LJ, Shenton ME, et al. (May 2009). "Abnormal pitch mismatch negativity in individuals with schizotypal personality disorder". Schizophrenia Research. 110 (1–3): 188–193. doi:10.1016/j.schres.2008.10.017. PMC   4285443 . PMID   19327968.
  200. ↑ Gilleen J, Tesse M, Velikonja T, Weiser M, Davidson M, Reichenberg A (September 2020). "Schizotypal traits and neuropsychological performance: The role of processing speed". Schizophrenia Research. 223: 128–134. doi:10.1016/j.schres.2020.06.030. PMC   7704687 . PMID   32631701. S2CID   220325569.
  201. ↑ Dickey CC, Morocz IA, Minney D, Niznikiewicz MA, Voglmaier MM, Panych LP, et al. (August 2010). "Factors in sensory processing of prosody in schizotypal personality disorder: an fMRI experiment". Schizophrenia Research. 121 (1–3): 75–89. doi:10.1016/j.schres.2010.03.008. PMC   2905482 . PMID   20362418.
  202. ↑ Mathur N, Dawes C, Moran PM (July 2019). "Olfactory threshold selectively predicts positive psychometric schizotypy". Schizophrenia Research. 209: 80–87. doi: 10.1016/j.schres.2019.05.014 . PMID   31160166. S2CID   171091790.
  203. ↑ Brenner CA, Sporns O, Lysaker PH, O'Donnell BF (December 2003). "EEG synchronization to modulated auditory tones in schizophrenia, schizoaffective disorder, and schizotypal personality disorder". The American Journal of Psychiatry. 160 (12): 2238–2240. doi:10.1176/appi.ajp.160.12.2238. PMID   14638599. S2CID   10677570.
  204. ↑ Niznikiewicz MA, Shenton ME, Voglmaier M, Nestor PG, Dickey CC, Frumin M, et al. (October 2002). "Semantic dysfunction in women with schizotypal personality disorder". The American Journal of Psychiatry. 159 (10): 1767–1774. doi:10.1176/appi.ajp.159.10.1767. PMC   2845844 . PMID   12359685.
  205. ↑ McClure MM, Barch DM, Flory JD, Harvey PD, Siever LJ (May 2008). "Context processing in schizotypal personality disorder: evidence of specificity of impairment to the schizophrenia spectrum". Journal of Abnormal Psychology. 117 (2): 342–354. doi:10.1037/0021-843X.117.2.342. PMC   4176884 . PMID   18489210.
  206. ↑ Kiang M, Prugh J, Kutas M (February 2010). "An event-related brain potential study of schizotypal personality and associative semantic processing". International Journal of Psychophysiology. Psychophysiology of Language Processes in Psychopathology. 75 (2): 119–126. doi:10.1016/j.ijpsycho.2009.10.005. PMC   2827666 . PMID   19818815.
  207. ↑ Kent BW, Weinstein ZA, Passarelli V, Chen Y, Siever LJ (April 2011). "Deficient visual sensitivity in schizotypal personality disorder". Schizophrenia Research. 127 (1–3): 144–150. doi:10.1016/j.schres.2010.05.013. PMC   2965789 . PMID   20541911.
  208. ↑ Harper L, Spencer E, Davidson C, Hutchinson CV (January 2020). "Selectively reduced contrast sensitivity in high schizotypy". Experimental Brain Research. 238 (1): 51–62. doi:10.1007/s00221-019-05695-9. PMC   6957544 . PMID   31781821.
  209. ↑ Ferri F, Ambrosini E, Costantini M (December 2016). "Spatiotemporal processing of somatosensory stimuli in schizotypy". Scientific Reports. 6 (1): 38735. Bibcode:2016NatSR...638735F. doi:10.1038/srep38735. PMC   5146666 . PMID   27934937. S2CID   11573502.
  210. ↑ Dalal TC, Muller AM, Stevenson RA (February 2021). "The Relationship Between Multisensory Temporal Processing and Schizotypal Traits". Multisensory Research. 34 (5): 511–529. doi:10.1163/22134808-bja10044. PMID   33706260. S2CID   232206767.
  211. ↑ Mannan MR, Hiramatsu KI, Hokama H, Ohta H (October 2001). "Abnormalities of auditory event-related potentials in students with schizotypal personality disorder". Psychiatry and Clinical Neurosciences. 55 (5): 451–457. doi:10.1046/j.1440-1819.2001.00889.x. PMID   11555339. S2CID   21236561.
  212. ↑ Niznikiewicz MA, Friedman M, Shenton ME, Voglmaier M, Nestor PG, Frumin M, et al. (May 2004). "Processing sentence context in women with schizotypal personality disorder: an ERP study". Psychophysiology. 41 (3): 367–371. doi:10.1111/1469-8986.2004.00173.x. PMC   2794422 . PMID   15102121.
  213. ↑ Dickey CC, Morocz IA, Niznikiewicz MA, Voglmaier M, Toner S, Khan U, et al. (August 2008). "Auditory processing abnormalities in schizotypal personality disorder: an fMRI experiment using tones of deviant pitch and duration". Schizophrenia Research. 103 (1–3): 26–39. doi:10.1016/j.schres.2008.04.041. PMC   3188851 . PMID   18555666.
  214. ↑ Hur JW, Kim T, Cho KI, Kwon JS (January 2021). "Attenuated Resting-State Functional Anticorrelation between Attention and Executive Control Networks in Schizotypal Personality Disorder". Journal of Clinical Medicine. 10 (2): 312. doi: 10.3390/jcm10020312 . PMC   7829946 . PMID   33467694.
  215. ↑ Trotman H, McMillan A, Walker E (July 2006). "Cognitive function and symptoms in adolescents with schizotypal personality disorder". Schizophrenia Bulletin. 32 (3): 489–497. doi:10.1093/schbul/sbj069. PMC   2632245 . PMID   16611879.
  216. ↑ Apthorp D, Bolbecker AR, Bartolomeo LA, O'Donnell BF, Hetrick WP (April 2019). "Postural Sway Abnormalities in Schizotypal Personality Disorder". Schizophrenia Bulletin. 45 (3): 512–521. doi:10.1093/schbul/sby141. PMC   6483590 . PMID   30376125.
  217. ↑ Niznikiewicz MA, Voglmaier MM, Shenton ME, Dickey CC, Seidman LJ, Teh E, et al. (October 2000). "Lateralized P3 deficit in schizotypal personality disorder". Biological Psychiatry. 48 (7): 702–705. doi:10.1016/S0006-3223(00)00938-0. PMC   2845845 . PMID   11032982. S2CID   18619922.
  218. ↑ Forsyth JK, Bolbecker AR, Mehta CS, Klaunig MJ, Steinmetz JE, O'Donnell BF, et al. (June 2012). "Cerebellar-dependent eyeblink conditioning deficits in schizophrenia spectrum disorders". Schizophrenia Bulletin. 38 (4): 751–759. doi:10.1093/schbul/sbq148. PMC   3406528 . PMID   21148238.
  219. ↑ Farmer CM, O'Donnell BF, Niznikiewicz MA, Voglmaier MM, McCarley RW, Shenton ME (May 2000). "Visual perception and working memory in schizotypal personality disorder". The American Journal of Psychiatry. 157 (5): 781–788. doi:10.1176/appi.ajp.157.5.781. PMC   2845849 . PMID   10784472.
  220. ↑ Shin YW, Krishnan G, Hetrick WP, Brenner CA, Shekhar A, Malloy FW, et al. (December 2010). "Increased temporal variability of auditory event-related potentials in schizophrenia and Schizotypal Personality Disorder". Schizophrenia Research. 124 (1–3): 110–118. doi:10.1016/j.schres.2010.08.008. PMC   3009463 . PMID   20817485.
  221. ↑ Goldstein KE, Hazlett EA, Savage KR, Berlin HA, Hamilton HK, Zelmanova Y, et al. (April 2011). "Dorso- and ventro-lateral prefrontal volume and spatial working memory in schizotypal personality disorder". Behavioural Brain Research. 218 (2): 335–340. doi:10.1016/j.bbr.2010.11.042. PMC   3049905 . PMID   21115066.
  222. ↑ Jones V, Steel C (September 2012). "Schizotypal personality and vulnerability to involuntary autobiographical memories" (PDF). Journal of Behavior Therapy and Experimental Psychiatry. 43 (3): 871–876. doi:10.1016/j.jbtep.2011.12.008. PMID   22269251. S2CID   7975363.
  223. ↑ Arzy S, Mohr C, Molnar-Szakacs I, Blanke O (January 2011). "Schizotypal perceptual aberrations of time: correlation between score, behavior and brain activity". PLOS ONE. 6 (1): e16154. Bibcode:2011PLoSO...616154A. doi: 10.1371/journal.pone.0016154 . PMC   3022658 . PMID   21267456.
  224. ↑ Bachetti MC, Cirimbilli F, Pierotti V, Menculini G, Tortorella A, Moretti P (September 2020). "A Dual Therapeutic Setting Model Experience for Schizotypal Personality Disorder in an Inpatient Unit" (PDF). Psychiatria Danubina. 32 (Suppl 1). Zagreb: 194–199. PMID   32890389.
  225. ↑ Rass O, Forsyth JK, Krishnan GP, Hetrick WP, Klaunig MJ, Breier A, et al. (April 2012). "Auditory steady state response in the schizophrenia, first-degree relatives, and schizotypal personality disorder". Schizophrenia Research. 136 (1–3): 143–149. doi:10.1016/j.schres.2012.01.003. PMC   3298621 . PMID   22285558.
  226. ↑ Dadić-Hero E, Ruzić K, Medved P, Tatalović-Vorkapić S, Graovac M (March 2010). "Antipsychotic side-effect - potential risk of patients rejecting their treatments". Psychiatria Danubina. 22 (1): 105–107. PMID   20305602.
  227. 1 2 Livesley W (2001). Handbook of personality disorders : theory, research, and treatment. Guilford Press. ISBN   978-1-57230-629-5. OCLC   45750508.
  228. ↑ Keshavan M, Shad M, Soloff P, Schooler N (November 2004). "Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder". Schizophrenia Research. 71 (1): 97–101. doi:10.1016/j.schres.2003.12.008. PMID   15374577. S2CID   12551427.
  229. ↑ McClure MM, Koenigsberg HW, Reynolds D, Goodman M, New A, Trestman R, et al. (August 2009). "The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder". Journal of Clinical Psychopharmacology. 29 (4): 396–398. doi:10.1097/JCP.0b013e3181accfd9. PMC   4176874 . PMID   19593186.
  230. 1 2 3 Kirchner SK, Roeh A, Nolden J, Hasan A (October 2018). "Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review". npj Schizophrenia. 4 (1): 20. doi:10.1038/s41537-018-0062-8. PMC   6170383 . PMID   30282970. S2CID   52914783.
  231. ↑ Jakobsen KD, Skyum E, Hashemi N, Schjerning O, Fink-Jensen A, Nielsen J (April 2017). "Antipsychotic treatment of schizotypy and schizotypal personality disorder: a systematic review". Journal of Psychopharmacology. 31 (4): 397–405. doi:10.1177/0269881117695879. PMID   28347257. S2CID   12170130.
  232. ↑ Miyazaki M, Simeon D, Hollander E (2017-05-01), "Treatment of Personality Disorders", The American Psychiatric Association Publishing Textbook of Psychopharmacology, American Psychiatric Association Publishing, doi:10.1176/appi.books.9781615371624.as51, ISBN   978-1-58562-523-9 , retrieved 2022-10-27
  233. 1 2 3 Koch J, Modesitt T, Palmer M, Ward S, Martin B, Wyatt R, et al. (March 2016). "Review of pharmacologic treatment in cluster A personality disorders". The Mental Health Clinician. 6 (2): 75–81. doi:10.9740/mhc.2016.03.75. PMC   6007578 . PMID   29955451.
  234. ↑ Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY (August 1991). "Fluoxetine in the treatment of borderline and schizotypal personality disorders". The American Journal of Psychiatry. 148 (8): 1064–1067. doi:10.1176/ajp.148.8.1064. PMID   1853957.
  235. ↑ Harrow M, Jobe TH, Faull RN, Yang J (October 2017). "A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia". Psychiatry Research. 256: 267–274. doi:10.1016/j.psychres.2017.06.069. PMC   5661946 . PMID   28651219.
  236. ↑ McClure MM, Harvey PD, Goodman M, Triebwasser J, New A, Koenigsberg HW, et al. (May 2010). "Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum". Neuropsychopharmacology. 35 (6): 1356–1362. doi:10.1038/npp.2010.5. PMC   3055340 . PMID   20130535. S2CID   7149320.
  237. ↑ Graff FS, McClure MM, Siever LJ (2014-12-01). "Remediation and Cognitive Enhancers in Schizotypal Personality Disorder". Current Treatment Options in Psychiatry. 1 (4): 369–375. doi: 10.1007/s40501-014-0027-0 . ISSN   2196-3061. S2CID   145447269.
  238. 1 2 McClure MM, Graff F, Triebwasser J, Perez-Rodriguez M, Rosell DR, Koenigsberg H, et al. (April 2019). "Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder". The American Journal of Psychiatry. 176 (4): 307–314. doi:10.1176/appi.ajp.2018.18030349. PMC   6443471 . PMID   30654644. S2CID   58626454.
  239. ↑ McClure MM, Barch DM, Romero MJ, Minzenberg MJ, Triebwasser J, Harvey PD, et al. (May 2007). "The effects of guanfacine on context processing abnormalities in schizotypal personality disorder". Biological Psychiatry. Multiple Genotypes and Brain Development in Schizophrenia. 61 (10): 1157–1160. doi: 10.1016/j.biopsych.2006.06.034 . PMID   16950221. S2CID   17772053.
  240. ↑ Arnsten AF, Jin LE (March 2012). "Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale". The Yale Journal of Biology and Medicine. 85 (1): 45–58. PMC   3313539 . PMID   22461743.
  241. ↑ Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, et al. (January 2015). "Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder". Neuropsychopharmacology. 40 (2): 446–453. doi:10.1038/npp.2014.192. PMC   4443959 . PMID   25074637. S2CID   30635726.
  242. ↑ Arnsten AF, Girgis RR, Gray DL, Mailman RB (January 2017). "Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia". Biological Psychiatry. Dopamine Hypothesis of Schizophrenia. 81 (1): 67–77. doi:10.1016/j.biopsych.2015.12.028. PMC   4949134 . PMID   26946382.
  243. ↑ McClure M, Perez-Rodriguez MM, Rosell D, Ejebe K, Siever L, New A (2019). "T38. Dopamine Enhancement of Verbal Learning in the Schizophrenia Spectrum". Schizophrenia Bulletin. 45 (Suppl 2): S218. doi:10.1093/schbul/sbz019.318. ISSN   0586-7614. PMC   6455598 .
  244. 1 2 Millon T (2004). "Chapter 12 – The Schizotypal Personality" (PDF). Personality disorders in modern life. Wiley. p. 403. ISBN   978-0-471-23734-1. OCLC   57291241. Archived from the original (PDF) on 2017-02-07.
  245. ↑ McGurk SR (April 2019). "Cognitive Remediation and Social Skills Training for Schizotypal Personality Disorder: Greater Gains With Guanfacine?". The American Journal of Psychiatry. 176 (4): 265–266. doi: 10.1176/appi.ajp.2019.19020144 . PMID   30929501. S2CID   89618769.
  246. ↑ McClure M, Graff F, Perez-Rodriguez M, Rosell D, Hazlett E, New AS, et al. (2017-03-01). "SA25. Guanfacine Augmentation of Cognitive Remediation Therapy in the Schizophrenia Spectrum: Prospects for Improving Cognitive Performance and Functional Skills". Schizophrenia Bulletin. 43 (suppl_1): S122. doi:10.1093/schbul/sbx023.024. ISSN   0586-7614. PMC   5475916 .
  247. 1 2 Stone MH (2014-05-05), "Paranoid, Schizotypal, and Schizoid Personality Disorders", Gabbard?s Treatments of Psychiatric Disorders, American Psychiatric Publishing, doi:10.1176/appi.books.9781585625048.gg68, ISBN   978-1-58562-442-3 , retrieved 2022-10-30
  248. ↑ McClure MM, Graff F, Triebwasser J, Perez-Rodriguez M, Rosell DR, Koenigsberg H, et al. (2019-01-18). "Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder". American Journal of Psychiatry. 176 (4): 307–314. doi:10.1176/appi.ajp.2018.18030349. ISSN   0002-953X. PMC   6443471 . PMID   30654644.
  249. ↑ Jeppesen UN, Due AS, Mariegaard L, Pinkham A, Vos M, Veling W, et al. (August 2022). "Face Your Fears: Virtual reality-based cognitive behavioral therapy (VR-CBT) versus standard CBT for paranoid ideations in patients with schizophrenia spectrum disorders: a randomized clinical trial". Trials. 23 (1): 658. doi: 10.1186/s13063-022-06614-0 . PMC   9377061 . PMID   35971137.
  250. ↑ Ryan A, Macdonald A, Walker E (2013). "The Treatment of Adolescents With Schizotypal Personality Disorder and Related Conditions: A Practice-Oriented Review of the Literature". Clinical Psychology: Science and Practice. 20 (4): 408–424. doi:10.1111/cpsp.12050 – via Wiley Online Library.
  251. ↑ Raine A, Mellingen K, Liu J, Venables P, Mednick SA (September 2003). "Effects of environmental enrichment at ages 3-5 years on schizotypal personality and antisocial behavior at ages 17 and 23 years". The American Journal of Psychiatry. 160 (9): 1627–1635. doi:10.1176/appi.ajp.160.9.1627. PMID   12944338.
  252. ↑ Oldham J, Skodol AE, Bender DS (2005). The American Psychiatric Publishing textbook of personality disorders. American Psychiatric Pub. ISBN   978-1-58562-159-0. OCLC   56733258.
  253. ↑ Siever LJ (1992). "Schizophrenia spectrum disorders". Review of Psychiatry. 11: 25–42.
  254. 1 2 3 "Schizotypal Personality Disorder (STPD) - Psychiatric Disorders". Merck Manuals Professional Edition. Retrieved 2023-03-11.
  255. ↑ Barrantes-Vidal N, Grant P, Kwapil TR (March 2015). "The role of schizotypy in the study of the etiology of schizophrenia spectrum disorders". Schizophrenia Bulletin. 41 (Suppl 2): S408–S416. doi:10.1093/schbul/sbu191. PMC   4373635 . PMID   25810055.
  256. ↑ Raine A (1991). "The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria". Schizophrenia Bulletin. 17 (4): 555–564. doi: 10.1093/schbul/17.4.555 . PMID   1805349.
  257. ↑ Moore TM, Calkins ME, Reise SP, Gur RC, Gur RE (May 2018). "Development and public release of a computerized adaptive (CAT) version of the Schizotypal Personality Questionnaire". Psychiatry Research. 263: 250–256. doi:10.1016/j.psychres.2018.02.022. PMC   5911247 . PMID   29625786. S2CID   5004186.
  258. ↑ Winterstein BP, Silvia PJ, Kwapil TR, Kaufman JC, Reiter-Palmon R, Wigert (2011). "Brief assessment of schizotypy: Developing short forms of the Wisconsin Schizotypy Scales". Personality and Individual Differences. 51 (8): 920–924. doi: 10.1016/j.paid.2011.07.027 .
  259. ↑ Schizotypal Disorder Archived 2015-11-02 at the Wayback Machine in ICD-10: Clinical descriptions and guidelines. Archived 2014-03-23 at the Wayback Machine
  260. 1 2 Gross GM, Mellin J, Silvia PJ, Barrantes-Vidal N, Kwapil TR (October 2014). "Comparing the factor structure of the Wisconsin Schizotypy Scales and the Schizotypal Personality Questionnaire" (PDF). Personality Disorders. 5 (4): 397–405. doi:10.1037/per0000090. PMID   25314229.
  261. 1 2 Parvaiz R, Vindbjerg E, Crespi B, Happe F, Schalbroeck R, Al-Sayegh Z, et al. (2023-03-28). "Protocol for the development and testing of the schiZotypy Autism Questionnaire (ZAQ) in adults: a new screening tool to discriminate autism spectrum disorder from schizotypal disorder". BMC Psychiatry. 23 (1). Springer Science and Business Media LLC: 200. doi: 10.1186/s12888-023-04690-3 . ISSN   1471-244X. PMC   10044373 . PMID   36978026.
  262. ↑ Nilsson M, Arnfred S, Carlsson J, Nylander L, Pedersen L, Mortensen EL, et al. (2019-05-03). "Self-Disorders in Asperger Syndrome Compared to Schizotypal Disorder: A Clinical Study". Schizophrenia Bulletin . 46 (1). Oxford University Press: 121–129. doi: 10.1093/schbul/sbz036 . ISSN   0586-7614. PMC   6942161 . PMID   34688345.
  263. ↑ The Millon Personality Group (8 March 2017). "Eccentric/Schizotypal Personality". Millon Theory. Archived from the original on 8 March 2017. Retrieved 5 April 2019.
  264. ↑ Livesley WJ, West M (1986). "The DSM-III Distinction between Schizoid and Avoidant Personality Disorders". The Canadian Journal of Psychiatry. 31 (1). SAGE Publications: 59–62. doi:10.1177/070674378603100112. ISSN   0706-7437. PMID   3948107. S2CID   46283956.
  265. ↑ McWilliams N (2011). Psychoanalytic Diagnosis: Understanding Personality Structure in the Clinical Process (2nd ed.). The Guilford Press. p. 199. ISBN   978-1-60918-494-0.
  266. ↑ McWilliams N, Lingiardi V, eds. (2017). Psychodynamic Diagnostic Manual (2nd ed.). The Guilford Press. ISBN   978-1-4625-3055-7.
  267. ↑ Correll CU, Smith CW, Auther AM, McLaughlin D, Shah M, Foley C, et al. (October 2008). "Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia". Journal of Child and Adolescent Psychopharmacology. 18 (5): 475–490. doi:10.1089/cap.2007.110. PMC   2779049 . PMID   18928412.
  268. 1 2 3 Pulay AJ, Stinson FS, Dawson DA, Goldstein RB, Chou SP, Huang B, et al. (2009). "Prevalence, correlates, disability, and comorbidity of DSM-IV schizotypal personality disorder: results from the wave 2 national epidemiologic survey on alcohol and related conditions". Primary Care Companion to the Journal of Clinical Psychiatry. 11 (2): 53–67. doi:10.4088/pcc.08m00679. PMC   2707116 . PMID   19617934.
  269. 1 2 3 Sutker P (2002). Comprehensive handbook of psychopathology (3rd ed.). Kluwer Academic. ISBN   978-0-306-46490-4. OCLC   50322422.
  270. ↑ Perris F, Fabrazzo M, De Santis V, Luciano M, Sampogna G, Fiorillo A, et al. (2019). "Comorbidity of Obsessive-Compulsive Disorder and Schizotypal Personality Disorder: Clinical Response and Treatment Resistance to Pharmacotherapy in a 3-Year Follow-Up Naturalistic Study". Frontiers in Psychiatry. 10: 386. doi: 10.3389/fpsyt.2019.00386 . PMC   6589899 . PMID   31263430.
  271. ↑ Murray R (2008). Essential psychiatry (4th ed.). Cambridge University Press. ISBN   978-0-521-60408-6. OCLC   298067373.
  272. ↑ Attademo L, Bernardini F (October 2021). "Schizotypal personality disorder in clinical obsessive-compulsive disorder samples: a brief overview". CNS Spectrums. 26 (5): 468–480. doi:10.1017/S1092852920001716. PMID   32713392. S2CID   220796175.
  273. ↑ Fossati A, Borroni S (2008). "When 'entities' are as intrusive as obsessions: A case study of the co-occurrence of obsessive–compulsive disorder and schizotypal personality disorder diagnoses". Personality and Mental Health. 2 (3): 192–200. doi:10.1002/pmh.42.
  274. ↑ Cavanna AE, Robertson MM, Critchley HD (December 2007). "Schizotypal personality traits in Gilles de la Tourette syndrome". Acta Neurologica Scandinavica. 116 (6): 385–391. doi:10.1111/j.1600-0404.2007.00879.x. PMC   2275799 . PMID   17986097.
  275. 1 2 Tasman A (2008). Psychiatry (3rd ed.). Wiley-Blackwell. ISBN   978-0-470-06571-6. OCLC   264703257.
  276. ↑ Walker E, Kestler L, Bollini A, Hochman KM (2004). "Schizophrenia: etiology and course". Annual Review of Psychology. 55 (1). Annual Reviews: 401–430. doi:10.1146/annurev.psych.55.090902.141950. PMID   14744221.
  277. ↑ Raine A (2006). "Schizotypal personality: neurodevelopmental and psychosocial trajectories". Annual Review of Clinical Psychology. 2: 291–326. doi:10.1146/annurev.clinpsy.2.022305.095318. PMID   17716072.
  278. ↑ Matsui M, Sumiyoshi T, Kato K, Yoneyama E, Kurachi M (April 2004). "Neuropsychological profile in patients with schizotypal personality disorder or schizophrenia". Psychological Reports. 94 (2). SAGE Publications: 387–397. doi:10.2466/pr0.94.2.387-397. PMID   15154161. S2CID   41869819.
  279. ↑ Haznedar MM, Buchsbaum MS, Hazlett EA, Shihabuddin L, New A, Siever LJ (December 2004). "Cingulate gyrus volume and metabolism in the schizophrenia spectrum". Schizophrenia Research. 71 (2–3): 249–262. doi:10.1016/j.schres.2004.02.025. PMID   15474896. S2CID   28889346.
  280. ↑ Kerridge BT, Saha TD, Hasin DS (2014). "DSM-IV schizotypal personality disorder: a taxometric analysis among individuals with and without substance use disorders in the general population". Mental Health and Substance Use. 7 (4): 446–460. doi:10.1080/17523281.2014.946076. PMC   4549000 . PMID   26322122.
  281. ↑ Giesbrecht T, Merckelbach H, Kater M, Sluis AF (October 2007). "Why dissociation and schizotypy overlap: the joint influence of fantasy proneness, cognitive failures, and childhood trauma". The Journal of Nervous and Mental Disease. 195 (10): 812–818. doi:10.1097/NMD.0b013e3181568137. ISSN   0022-3018. PMID   18043521. S2CID   45086235.
  282. ↑ @unknown{unknown, author = {Šram, Zlatko}, year = {2018}, month = {03}, title = {Childhood Trauma, the Occult, Dissociative Identity Disorder, and Schizotypal Personality Disorder: Relations on a Sample of Psychiatric Outpatients} }https://www.researchgate.net/publication/323526162_Childhood_Trauma_the_Occult_Dissociative_Identity_Disorder_and_Schizotypal_Personality_Disorder_Relations_on_a_Sample_of_Psychiatric_Outpatients
  283. ↑ "APA PsycNet". psycnet.apa.org. Retrieved 2023-03-12.